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ABSTRACT 
Cholecystokinin (CCK) comprises a group of related peptides all 
sharing a common (OOH-terminal pentapeptide sequence with gastrin. 
At least six molecular forms have been described ; a larger com-
ponent with molecular weight more than 4 000, CCK 39, CCK 33, 
The development of radioimmunoassays 
2 
for CCK, using antisera specific for CCK and not gastrin and radio-
label I ing using the Bolton-Hunter reagent led to rapid advances in 
the field. 
CCK was found to be present in high concentrations throughout the 
as compared to gastrin which 
was only found in the adeno and neuro-hypophysis and pituitary 
central nervous system and small bowel 
stalk regions of the brain but with a wide distribution in the gut. 
The highest concentration of CCK in the brain occurs in the cortex, 
in contrast to other hormonal brain peptides where the highest concen-
tration has been found in the hypothalamus. Two related but differ-
ent forms of CCK 8 account for over 90'% of the immunoreactive CCK 
found in the rat brain; one being identical to CCK 8 • 
In this thesis the in vitro release of immunoreactive CCK8 (iCCK8) 
from rat central nervous system preparations and the 
release have been studied. Rat brain was dissected 
regions ; hypothalamus, cerebral cortex, striatum and 
to the method of Brownstein, Arimura, Sato et. al. 
was found to be distributed throughout these regions 
regulation 
into the 
thalamus, 
(1975). 
{range of 
of this 
following 
according 
CCK 8 
9 - 300 
pmoles), with the highest concentration in cortex (300 pmol). In 
addition, low levels {range 9 - 30 pmoles) of CCK8 were found in 
spinal cord, brain stem and cerebellum, in agreement with other workers. 
lmmunohistochemical techniques have demonstrated CCK-1 ike immuno-
reactivity in nerve cell bodies and fibres throughout brain, particularly 
in the cortex. Subcel lular fractionation of rat brain was used to 
study the subcel lular localisation of CCK. Tissue was homogenised to shear 
off nerve terminals (synaptosomes) which were purified and used to 
study the release of the peptide from hypothalamic and extra-
hypothalamic nerve endings. 
The distribution of CCK8 from tissue homogenates prepare
d on 
continuous sucrose density gradients from four different brain areas 
was found to coincide 
transmitter uptake. 
noradrenaline uptake 
The 
closely with the profile of label led neuro-
peaks of CCK 8, r4c] choline and [ 3H] 
were found in fractions shown by electron mi-
croscopy to consist mainly of synaptosomes. The purified synap-
tosomal pellet obtained by differential centrifugation on a discontin-
uous sucrose density gradient contained the major concentration of 
gradient protein, occluded lactate dehydrogenase activity (an enzyme 
found in high concentrations in the synaptosomal fraction of brain 
homogenates) and CCK 8 immunoreactivity. CCK 8 was released from 
synaptosomes prepared from hypothalami, striatum, cortex and thalamus 
by the depolarising stimuli of 60 mM KCI and 75 JJM veratrine in a 
calcium-dependent manner. 
The high concentrations and widespread distribution of CCK8 in the 
CNS, the localisation in, and release from, synaptosomes, together 
3 
with evidence that CCK8 has central actions on feeding behaviour 
suggests that the peptide may have a regulatory function at the synap-
tic level. Thus a new technique was developed to study the release 
of CCK 8 from synaptosomes. 
Instead of the traditional static procedure in which synaptosomes are 
incubated and the released substance measured in the supernatent (as 
described above) a new technique was developed involving perifusion 
of synaptosomes. The highest concentration of CCK8 in the brain is 
present in cerebral cortex und thus this region was 
preparation of synaptosomes in the perifusion study. 
validation of the perifusion system has been described 
Using 
ising 
this 
stimuli 
technique CCK8 
of 100 mM KCI 
was found 
and 
dependent manner. 
-6 ( at 1 0 M) caused 
Dopamine 
a significant 
(at 
release 
to be released 
veratrine in 
and l0-8M) 
of CCK 8 from 
used for the 
The method and 
in detail. 
by the de polar-
a calcium-
and acetyl choline 
perifused synap-
4 
-4 
tosomes. Noradrenaline and serotonin at concentrations of 10 M, 
10-6M and 10-BM had no effect. 
lmmunocytochemical studies have shown the presence of CCK-1 ike immuno-
reactivity in the dorso medial nucleus of the hypothalamus. In this thesis it 
has been shown that CCK 8 is localised in, and released from, hypothalamic 
synaptosomes, suggesting that it may have a role in the regulation of pituitary 
function. CCK 8 has been shown to release 
growth hormone (GH) from isolated 
rat pituitaries. The structurally related peptide, pentagastrin, also 
stimulates growth hormone secretion in man. 
In view of this possible hypophysiotrophic role for this peptide as a 
regulat0r of GH, the in vitro incubated rat hypothalamus was used 
to investigate hypothalamic release of CCK 8• The depolarising stimuli 
of 60 mM KCI and 
a calcium-dependent 
75 µM 
manner. 
veratrine were 
Dopamine 
found to 
-4 
at 10 M, 
concentrations caused a significant release of CCK 8• 
release CCK 8 in 
10-6M and l 0-BM 
The dopamine 
stimulated CCK 8 release appeared to be dependent upon noradrenergic 
modulation as demonstrated by our findings that phentolamine at 
physiological concentrations inhibited dopamine stimulated release. No 
inhibition of dopamine stimulated release could be demonstrated by 
somatostatin (SRIF) or rat growth hormone (rGH). Th is does not how-
ever exclude a GH releasing role of CCK 8 either at a hypothalamic 
or pituitary level. The lack of effect on CCK 8 release by a number 
of other neurotransmitters confirmed the specificity of the observed 
stimulatory responses in this system. 
In order to characterise the peptide, extracts of the brain areas 
and released material from the preparations used were subjected to 
Sephadex G-50 (sf) and high pressure liquid chromatography and found 
to coelute with synthetic CCK 8 • No material coeluted with gastrin 
or the larger molecular species of CCK. Serial dilutions of the 
above samples showed parallel ism with synthetic CCK 8 in the radio-
immunoassay. In addition, other CCK moieties such as CCK 33 and 
CC K 4 crossreact poorly with the antiserum used, and the low concen-
tration of gastrin as compared to CCK in the brain rendered the assay 
5 
relatively specific for CCK 8 • 
In summary these studies show 
1. 
2. 
3. 
4. 
5. 
CCK
8 is present in rot brain with a wide and uneven 
distribution. 
CCK8 is localised to the synaptosome fraction of hypo-
thalamus, striatum, cerebral cortex and thalamus which can 
be released by depolarising stimuli in a calcium-dependent 
manner. 
The establishment of a perifusion system for cortical synap-
tosomes has proved to have several advantages over the 
static method. 
Using this technique dopamine and acetyl choline (l0-6M) 
caused release of CCK
8 while serotonin and norodrenal ine 
had no effect. 
Incubated hypothalami released CCK
8 in a calcium-dependent 
in response to depolarising stimuli. Dopamine 
l o-6M and l0-8M) stimulated release of CCK
8 
while other neurotransmitters had no effect. 
These findings indicate 
1. 
2. 
The distribution of CCK 8 in brain, and its localisation and 
release from synaptosome fractions, by depolarising stimuli 
and neurotransmitters suggests a neuromodulatory role for CCK 8• 
Release of CCK8 from isolated hypothalami is consistent with 
the suggested role of CCK 8 in pituitary hormone regulation. 
,8. 
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LITERATURE REVIEW 
SECTION Cholecystokinin as a Gut and Brain Peptide 
PEPTIDES OF THE GUT AND BRAIN 
Classical endocrinology and the fundamental concept of control of 
bodily functions by substances produced by distant organs originated 
after Brown-Sequard's experiments where he showed bodily functions 
recovered after treatment with extracts of the failing organ. 
Further support to this concept was given by the work of Bayliss 
and Starling (1902), who strongly substantiated the idea that "control 
of bodily functions was elicited by circulating chemical messengers". 
They proposed the word 'hormone' be used for these substances. 
These same workers (Boyl iss and $tori ing, 1903) suggested that the 
control mechanisms of gut function were hormonally mediated, being 
both simple and uniform throughout the vertebrates. A large number 
of biologically active peptides have since been identified in the 
gastrointestinal tract and have been designated the 'gut hormones' • 
Until recently the gut hormones were thought to be an isolated 
system more or less exclusively concerned with the regulation of 
digestion. Von Euler and Gaddum (1931), however, showed that 
an identical substance was present in both the gut and brain thus 
disputing the concept of independent endocrine functions of the gut 
and brain. Rapid advances in the fields of neuroendocrinology and 
gastrointestinal endocrinology have shown that gut endocrine cells 
produce peptides found in a wide variety of other tissues including 
pancreas, pituitary and the central and peripheral nervous system. 
The finding that similar peptides are found in both the gut and 
brain prompted a re-evaluation of their mode of action. There is 
now strong evidence that the chemical messengers, be they 'neuro-
transmitters', 'neurohormones' or 'gut hormones', may reach their targets 
by 
i) 
ii) 
entering the bloodstream to reach and alter the activity 
of distant eel Is {endocrine or hormonal effect) 
diffusing locally through interstitial spaces to reach and 
influence groups of neighbouring cells {paracrine) 
iii) crossing a synaptic junction to activate or inhibit synaptic 
transmission (neurocrine). 
At least ten peptides or groups of peptides are known to, or are 
suspected of mediating regulatory effects via endocrine, paracrine 
or neurocrine mechanisms in nerve cells of the gut and brain and 
in mucosa! cells of the gut. {Table 1. 1) 
B EVOLUTION OF NEUROPEPTIDES 
This dual distribution and similarities in the amino acid sequences 
of some of these peptides along with other chemical properties led 
Pearse (1976) to suggest that these eel Is may share a common 
embryological origin in the neuroectoderm. He called these eel Is 
the APUD ce tis because al I had the characteristic property of 
11 
amine 
ever, 
precursor uptake 
have failed to 
and decarboxyl at ion. Recent experiments, 
demonstrate a neuroectodermal origin for the 
how-
gut 
and pancreatic endocrine cells {Andrew, 1976 ; Fontaine and Le Douarin, 
1977 ; Pictet, Rall, Phelps et. al. 1976) but indicate an endodermal 
origin (Dockray, 19790). Dockray (1979b) has suggested that this 
dual distribution of peptides in nerves and endocrine cells should be 
regarded as the capacity of all eel Is to produce a particular peptide 
which can be drawn on independently by different cell types so that 
the same peptide functions in unrelated systems. 
The related sequences of gastrin and CCK, and secret in, glucagon, 
vasoactive intestinal polypeptide (VIP) and gastric inhibitory peptide 
(GIP), and substance P and neurotensin indicate evolution from common 
ancestral molecules by gene duplication fol lowed by divergence due to 
point mutation and amino acid substitution (Barrington and Dockray, 1976 ; 
12 
Table 1.1 
Peptides Common to Brain and Endocrine Cells of the Gut 
Peptide 
Sustance P 
Somatostatin 
LEU and MET Enkephalin 
Vaso-active Intestinal peptide 
Neurotensin 
Bombesin 
Cholecystokinin 
Gastrin 
Thyrotrophin releasing hormone 
Adrenocort icotroph ic hormone 
Author 
Pearse and Polak, (1975) ; 
Nilsson, Larsson, H8kanson et. al., 
(1975) 
Polak, Grimelius, Pearse et. al. , 
(1975) ; Brownstein, Arimura, Sato 
et • a I . , ( l 97 5) 
Smith, Kosterl itz, et. al. Hughes, 
(1975) ; 
(1977b) 
Polak, Sullivan, Bloom et. 
G iachetti, 
(1977) ; 
(1976) 
Said, 
Bryant, 
Reynolds et. 
Polak, Modlin 
al. I 
et. 
I 
al. 
al. 
Polak, Sullivan, Bloom et. al. , (1977a) 
Polak, Ghatei, Wharton et. al. , (1978) 
Rehfeld, 0978a, b) 
Rehfeld, (1978c) ; Rehfeld, Stadil, 
Malmstrom et. al. ' (1975) 
Loonen and Soudijn, (1979) 
Larsson, (1980) 
I 
I 
Dockray, 1979b). Deletion and insertion in the structural gene 
(Track, 1973) and mutations affecting post-transcriptional splicing of 
mRNA (Gilbert, 1978) may well account for the molecular diversity 
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of the gut hormones with functionally important residues being conserved. 
Thus the COOH-pentapeptide common to gastrin and cholecystokinin 
(CCK) also contains their minimal active fragment. 
It is now be I ieved that once an organ ism has established the 
capacity to produce a particular peptide, this capacity can be 
drawn on independent! y by different ce II types by changes in the 
pattern of gene expression. Thus the same peptide being present 
in brain and gut is an example of biological conservation. For 
this view to be correct, a molecular messenger, receptor and de-
grading pathway must exist that can be used in different systems 
regulating different functions in the same organism (Dockray, 197~ 
this dual 
vertebrate 
distribution in brain 
I ine ; representatives of 
have CCK-1 ike factors 
and gut was 
the oldest 
in 
It has been shown that 
es tab I ished early in the 
vertebrate group, the 
endocrine cells and 
cyclostomes, 
brain (Dockray, 1979a). Larsson and 
gut 
Rehfeld 
(1977) using antisera specific for different regions of mammalian gastrin 
and CCK were unable to find separate gastrin and CCK-1 ike peptides 
in both amphibia and teleosts. These hormones, however, have been 
localised to different populations of gut endocrine cells in reptiles 
and birds. (Larsson and Rehfeld, 1977 ; Dockray, 1978). On the 
basis of this evidence it has been postulated that the evolutionary 
divergence of these two hormones occured after the amphibian and 
reptilian lines separated. However, it cannot be excluded that there 
exists in the amphibia and lower vertebrates gastrin-1 ike peptides that 
do not cross-react with the mammalian antiserums. 
studies indicate that in mammals each member of the 
its own cell of origin with a characteristic distri-
1979b). In lampreys and protochordotes both gl ucagon 
lmmunocytochemi cal 
gastrin family has 
but ion (Dockray, 
and gastrin-1 ike 
that the two 
immunoreactivities occur in the same cell suggesting 
main families of gut hormones were originally the 
product of a single cell type (Van Noorden and Pearse, 1974 ; 
Von Noorden and Pearse, 1976). 
Many secretory peptides ore the product of proteolytic cleavage of 
large precursor peptides. CCK 39 is probabl
y the precursor of the 
33-residue form, isolated from intestine (Mutt, 1976). CCK 8 has 
been found in brain (Dockray, Gregory, Hutchison et. al. , 1978) 
and intestine (Dockray, 19770) but only relatively small amounts of 
the larger forms of CCK have been found in brain suggesting that 
conversion of larger to smaller forms is more or less complete in 
nerves but incomplete in gut endocrine cells. Recent studies on 
14 
other peptides (Mains and Eipper, 1978 ; Moody, Jacobson and Sundby, 
1978 ; T ager and Steiner, 1973) supports the idea that the some 
precursor may be produced in different cell types and then processed 
differently. In addition it has been postulated that distinct peptides 
can be derived from a single biosynthetic precursor. There is 
evidence, for example, that p lipotrophin (p LPH) is a product of 
a larger precursor (31K) which contains the sequence for cortico-
trophin (Mains, Eipper and Ling, 1977) and that p LPH is a 
precursor for p me I anotroph in and the endorphins. 
The post-translational processing of the precursor peptides directly 
determines the activity of the final product. During evolution the 
enzymes involved In these processing pathways must be subject to 
natural selection. Conservation of the mechanism for proteolytic 
cleavage of CCK 8 precursor 
forms is suggested by the fact that 
peptides ore found in lampreys and mammals of similar size to CCK8• 
Lastly there is now evidence supporting the theory that evolutionary 
changes in target organ receptor mechanisms occurs to match those 
of their ligands (Holste·in, 1975 ; Dockray, 1977b). In the cyclo-
stomes the digestive tract is a simple tube and since they possess 
CCK-1 ike peptides there exists the elements for hormonal control. 
This might be by local paracrine mechanisms that later give way 
to endocrine control mechanisms for as Barrington (1971) has pointed 
out "it is difficult to see how the pancreas could have evolved 
15 
without simultaneous development of mechanisms for its control". 
It has 
sulphated 
been shown that both teleosts and mammals require a 
tyrosine residue to stimulate gal I bladder contraction. 
In mammals, however, the 
all important for contraction 
precise location required for 
position of 
while in 
potency 
the sulphated tyrosine 
there is the teleosts 
(Vigna and Gorbman, 
is 
no 
1977). 
Evolution of endocrine systems depends on the action of natural 
selection on inherited variability. The existence of a pool of 
variability in receptors provides a mechanism 
structurally related peptides can exert specific 
for understanding how 
actions on different 
target organs. In particular, an 
clarify mechanisms governing the 
evolutionary approach 
function and production 
can 
of 
help 
the 
same peptides in both endocrine eel Is and neural tissue. 
C. CHOLECYSTOK ININ 
C l) Historical Aspects 
CCK together with gastrin and secretin, comprise the three classical 
and es tab I ished gastrointestinal hormones. In 1928, Ivy and Oldberg 
found a hormone that would stimulate gallbladder contraction and 
named it cholecystokinin. Later Harper and Raper (1943) found a 
hormone that would stimulate pancreatic enzyme secretion and called 
it pane re oz ym in. It was not un ti I 1968 that J orpes showed that 
these two hormones were identical. The hormone is now called 
cholecystokinin, since stimulation of gallbladder contraction was the 
first action described. 
C 2) Isolation and Structure 
CCK was first isolated by Mutt and Jorpes (1967) from hog duodenal 
extracts and was chemically characterised and shown to contain 33 
amino acid residues (Jorpes, 1968 ; Thompson, 1973) 
the sequence of which is now determined {Mutt and 
and confirmed in part by synthesis (Ondetti, Pli.Ml:!ec, 
(1970). Subsequent! y a CCK variant {CCK 39) with a 
(Fig 1.1) 
Jorpes, 1971) 
Sabo et. al. , 
further six 
H2N t TYR - ILE 
0 
Fig l. l 
CCK 
39 
- GLN - GLN - ALA - ARG 
I 
SER 
I 
GLY 
I 
ARG 
10 
, 
ASN - LYS - ILE - MET - SER - VAL 
LEU 
GLN 
I 
SER 
CCK 33 
I 
LEU 20 
I 
ASP - PRO - SER - HIS - ARG - ILE 
/ I 
30 
I SER 
I I 
~\ ASP I 
~ \ ~ , AR,G 
ASP 
C - PHE - ASP - MET - TRP - GL Y - MET 
'7 2""22 -,,I 
CCK 4 
Structure of CCK 33 and its variant CCK 39• 
the smaller molecular weight forms. 
Brackets indicate 
16 
17 
amino acid residues linked to the NH 2 terminus of the triacontatria-
peptide was described (Mutt, 1976 Debas and Grossman, 1973). 
A striking feature of both CCK 's 1s that the (OOH-terminal penta-
peptide sequence, which contains the biologically active region (Mutt 
and Jorpes, 1967) of the molecule is identical with the COOH-
terminal region of the four characterised molecular forms of gastrin 
(Gregory and Tracy, 1964; Rehfeld, 1972; Gregory and Tracy, 1975). 
The crucial difference between gastrin and CCK is the location of 
the sulphated tyrosine residue (Fig 1. 2). In gastrin it 1s in 
position 6 and CCK in position 7 (counting from the (OOH-terminus). 
All known gastrins occur naturally in both the sulphated (G-11) and 
the unsulphated (G-1) form (Gregory, 1968) whereas CCK occurs 
naturally in the sulphated form. Desulphation results in loss of 
effect on the gallbladder and alters it to the gastrin-like pattern 
of activity in acid secretion (Johnson, Stening and Grossman, 1970). 
Smaller molecular forms than CCK 33, also having a common pen ta-
peptide sequence with gas tr in have been characterised. Vanderhaeghen, 
S igneau and Gepts (1975) found a peptide in brain that reacted 
with gastrin antibodies. This was later shown to correspond to CCK 8-
like material (Dockray, 1976). Subsequent reports have found 
i) CCK 8-like material in brain and intestine (Dockray, 1976 ; 
Mui ler, Straus and Yalow, 1977 ; Rehfeld, 1978b ; Dockray, 
ii) 
Gregory, Hutchison, 
A 
in 
closely related 
brain (Dockray, 
et. al. I 1978 ; Dockray, 1977a). 
but slightly less acidic form than CCK
8 
Gregory, Hutichison, et. al. , 1978). 
iii) CCK 4 -1 ike material in brain and gut (Rehfeld, 1978b ; 
Rehfeld and Goltermann, 1979 ; Rehfeld and Larsson, 1979). 
iv) CCK 12-like material in the gut (Rehfeld, 1978b). 
v) A minor component of 4 - 6 residues in brain (Dockray, 
1976). 
vi) A larger component than CCK 39 in gut (Dockray, 1978b ; 
Rehfeld, 1978b). 
A. 
B. 
Fig 1.2 
Comparison of the amino acid structure of CCK 33 and G 34 
I 
I 
I 
I 
-Lys-Ala-Pro 
I I I 
l l Ser 
: SQ I 
0
,, 33 30 ! / 3 20 10 G,ly 
C -Phe-Asp-Met-Trp-Gly-Met-Tyr-Asp-Arg-Asp-Ser-lle-Arg-His-Ser-Pro-Asp-Leu-Ser-Gln-Leu-Asn-Lys-lle-Met-Ser-Val-Arg 
, I 
NH 2 ! 
I 
I 
I 
I Q I ~ I 
;c-Phe-Asp-Met-T rp-G ly-Tyr-A la-GI u-G lu-G lu-GI u-G lu-Leu-T rp-Pro-G ly-G 11-Lys-Lys-Ser-Pro-Asp-Ala-Va I-Leu-Ser-Pro-His 
NH2 34 30 : , , 20 10 ' 
• H so3 G1ly 
Gin 
I 
Glp-Leu-Gly-Pro 
1 
The amino acid sequence of cholecystokinin - 33 (A) compared to the amino acid sequence of gastrin - 34 (B). 
Both peptides share the same peptapeptide sequence ; 29 - 33 in CCK and 30 - 34 in gastrin. 
may be sulphated or non-sulphated on Tyr 29 whereas CCK is always sulphated on Tyr 27. 
gastrin (G-17) is also demarcated (18 - 34 of G-34). 
Gas tr in 
Heptadecapeptide o: 
19 
Rehfeld and Larsson (1979) have suggested that CCK 4 predominates in 
the gut whereas the two CCK 8-like peptides Dock
ray, Gregory, 
Hutchison et. al. (1978) have isolated so far, account for the 
majority of the (OOH-terminal immunoreactivity in the brain. CCK 4 
has a higher immunochemical potency than CCK 8 and therefore cann
ot 
be excluded as the major active form in brain. Si nee the tetra-
peptide amide contains essentially all the biological information present 
in gastrin and CCK, it has been postulated by Rehfeld and Larsson 
(1979) to be the principal neurotransmitter of the gastrin/CCK family. 
C 3) Distribution in the Gut 
Along with gastrin, CCK has been found to have a wide distribution 
in the gut of all species. High concentrations have been found in 
the duodenum, jejunum, ileum (Reeder, Becker, Smith et. al. I 1973; Bloom 
and Bryant, 1973), mucosa of the upper small intestine (Jorpes, 1968) 
and mucosa of the small bowel (Polak, Pearse and Bloom, 1975). 
Both CCK and gastrin have been localised to nerve terminals in the 
gut (Uvnas-Wal lensten, Rehfeld, Larsson et. al., 1977 ; Rehfeld, Larsson, 
Goltermann et. al. I 1980) and found to be present in distinct 
endocrine cells, gas tr in to the G cell (Solcia, Vassallo and Capella, 
1970) and CCK to the cell (Buchan, Polak, Solcia et. al. I 1978). 
C 4) Actions in the Gut 
Both CCK and gastrin have a wide range of actions in the gut 
(Table l • 2) The various molecular forms of CCK and gas tr in have 
different potencies for the actions listed in Table 1.2. for example, 
CCK 8 has a higher potency than
 CCK 33 for gal I bladder c
ontraction 
and CCK 33 a higher potency than G-17, wherea
s CCK4 is more 
potent than G-17 in insulin release. One must differentiate between 
physiological and pharmacological actions of these peptides according to 
the potency and concentration of peptide in each case. Thus the 
action of G-17 on acid secretion is physiological, whereas its action 
on gal I bl odder contraction is probably pharmacological. 
l. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
Table 1.2 
Actions of CCK and Gastrin in the Gut 
Stimulation of exocrine pancreatic secretion 
bicarbonate. 
Stimulation of pancreatic endocrine secretion 
enzymes and 
insulin, 
somatostatin, glucagon and pancreatic polypeptide. 
Stimulation of gastric acid and pepsin secretion. 
Stimulates secretion of Brunner's glands. 
Stimulates smooth muscle contraction in gal I bladder, stomach 
and intestine. 
Inhibition of lower oesophageal sphinctre and sphinctre of 
Oddi. 
Stimulates blood flow in superior mesenteric artery. 
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Modulates intestinal absorption of water and electrolytes from 
jejunum and ileum. 
Trophic action on the parietal mucosa (gastrin) and pancreas 
(CCK). 
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D. CCK IN BRAIN 
In 1975, Vanderhaeghen, Signeau and Gepts found a new peptide 
in the vertebrate central nervous system (CNS) that reacted with 
antibodies against gastrin. At this time it was unclear what was 
actually being measured due to the fact 
the COCH-terminus of gastrin cross-reacts 
using extracts of vertebrate CNS tried to 
between gastrin-1 ike activity in brain and 
gastrin and CCK. He showed that the 
that antiserum specific 
with CCK. Dockray, 
clarify the relationship 
the characteristic forms 
chromatographic profile 
for 
(1976) 
of 
of 
th is material on Sephadex G-25 differed from the previously charac-
terised forms of gastrin and CCK eluting in the same position as 
the COCH-terminal octapeptide of CCK (CCK 8). The pattern of 
reactivity with six different COCH-terminal specific gastrin antisera 
which also cross -reacted with CCK suggested that the brain peptide 
resembled CCK 8 immunoreactivity more closely than gastrin-like 
peptides. 
In 1977, Mui ler, Straus and Yalow, using extracts of pig cerebral 
cortex found two components, one resembling CCK 33 in size, charge 
and immunological specificity and the other resembling the COOH-
terminal octapeptide. The relative concentrations of each depended 
on the extraction technique used. 
Immunological reactions are not necessarily identical to those responsible 
for biological activity. Robberecht, Deschodt-Lanckman and Vander-
haeghen (1978), however, showed that water-boiled extracts of this 
COCH-terminal octapeptide, taken from post mortem human grey matter 
displayed biological activity of CCK on rat poncreatic preparations. 
These biological studies, immunological techniques and fractionation 
procedures involving size and charge showed that this material was 
closely related to biologically active CCK
8
• 
Dockray, Gregory, Hutchison et. al. (1978) detected three components 
(SBI, II and Ill) with CCK-like immunoreactivity in sheep brain. 
Two (11 and 111) have been iso I ated in amounts of 150 - 300 f'g/1 00kg 
fresh brain by gel filtration, ion-exchange chromatography and column 
electrophoresis, the third in amounts of 50 µg/100kg fresh brain is 
not yet homogenous. SBI II was found chemically, biologically and 
immunochemical ly to be indistinguishable from synthetic CCK 8 and 
SBII, present in approximately equal amounts, to be a closely 
related analogue, the difference between them remains to be est-
obi ished. 
Rehfeld (1978b) while studying extracts of tissues from the CNS and 
small intestine of adult man and hog, extracted at different pH 1s 
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found seven different molecular forms of CCK. These were found to 
be similar to a larger peptide than CCK 39, CCK 39, CCK 33, CCK 12, CCK 8 
and two smaller molecular forms than the octapeptide. These were 
later found to resemble the NH 2 and the COCH-terminal tetrapeptide 
fragments of CCK 8 (Rehfeld and Goltermann, 1979). It is unlikely 
that these two peptides arise artifactual ly during extraction because 
CCK 33 and CCK 8 are both stable during boiling water extraction and 
also these peptides have since been found in normal unextracted CSF 
(Rehfeld and Kruse-Larsen, 1978). 
The COCH-terminal tetrapeptide-1 ike components appeared to be present 
in larger amounts than CCK 8 (Rehfeld and Goltermann, 1979). The 
fact that peptides corresponding to both the NH 2 and COCH-terminal 
parts of CCK8 occur in cerebral cortex, suggests that the peptides 
arise from 
present in 
post translational 
cortex. These 
cleavage of CCK 8 which is abundantly 
workers have suggested that CCK 4 is the 
active neuropeptide in brain. 
D 1 Cholecystokinin Converting Enzyme 
It has been shown over the last ten years that many peptide hormones 
are found in their tissues of origin in more than one molecular form. 
It is generally thought that the larger molecular weight form is a 
prohormone of the smaller molecular weight forms if it contains an 
amino acid sequence identical to, or if it is convertible by enzymatic 
conversion to a smaller, wel I characterised and more biologically active 
form, whether or not the biosynthetic precursor relationship has been 
established (Straus, Malesci and Yalow, 1978). CCK is found in 
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tissue as a range 
potencies (Rehfeld, 
of molecules of different sizes and 
1978b ; Gregory and Tracy, 1972 ; 
biological 
Rehfeld, 1972 ). 
Thus a precursor relationship or prohormone function 
and Jorpes, 1968) 
has been assumed 
for a) CCK 39 and CCK 33 
and CCK 12 and CCK 8, the 
biological potencies than the 
(Mutt 
COOH 
and b) CCK33 
The amount of 
greater m the 
extracts might 
CCK 33 to the 
fragments that have greater 
presumed precursor CCK 33• 
immunoreactivity in components smaller than 
brain than in the gut and suggested that 
contain a high potency enzyme that would 
smaller hormonal forms. 
CCK 33 
brain 
convert 
is 
Straus, Malesci and Yalow (1978) characterised and partially purified 
an enzyme from extracts of mammalian brain which converts porcine 
CCK 33 to smaller molecular weight forms. This enzyme has since 
been purified (Malesci, Straus and Yalow, 1980) and shown to 
consist of at least two separate but closely related enzymes, one 
cleaving at the Arg-lle bond to yield CCK 12 and the other at 
the Arg-Asp bond to yield CCK 8 • These enzymes differ from trypsin 
in substrate specificity in that they fail to convert G-34 to G-17 
and in several physiochemical 
stab ii ity and behaviour in the 
properties, i.e. molecular size, temperature 
no evidence 
and porcine 
It is not 
presence of trypsin inhibitor. There was 
that the enzyme was species 
extracts were equally effective 
yet known whether the enzyme 
specific in that both canine 
in cleaving porcine CCK 33 • 
that must exist m the gut 
resembles or is different from that found in the brain. 
D 2) Distribution and Concentrations of CCK in the Brain 
CCK-like peptides have been found in large amounts in the brain 
and gut of vertebrates and invertebrates; humans (Rehfeld, 1978b), 
pigs (Muller, Straus and Yalow, 1977), sheep (Dockray, Gregory, 
Hutchison et. al. , 1978), monkeys, dogs (Straus and Yalow, 1979a), 
/ 
rats, (Loren, Alumets, H8kanson et. al. , 1979), birds, (Dockray, 1978), 
fish and amphibia (Larsson and Rehfeld, 1977). Species differences 
occur in the NH2 portion of CCK 33 (Straus and Yalow, 1978). 
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Rehfeld (1978b) reported differential distribution of CCK in the pig 
CNS with highest concentrations in the cerebral cortex, 200 - 2,300 
p mol/g ; corpus striatum, 158 - 480 p mol/g ; hypothalamus, 24 - 220 
p mol/g mesencephalon, 13 - 93 p mol/g ; thalamus, 8 - 59 p mol/g 
and brain stem, 6 - 43 p mol/g. CCK was undetectable in the 
pineal body, pituitary gland, cerebellum and pons. Rehfeld (1978b) 
suggested that CCK was unique among the hormonal brain peptides 
in that 
i) 
ii) 
CCK is predominantly located in the cerebral cortex 
which dominates the CNS rn man whereas TRH (01 iver, 
Eskay, Ben-Jonathan et. al. , 1974 ; Winokur and Utiger, 
1974), SRIF (Brownstein, Arimura, Sato et. al. , 1975), 
substance P (Brownstein, Mroz, Kizer et. al. , 1976), 
VIP (Larsson, Fahrenkrug, Schaff al itzky De Muckadell et. 
al. , 1976 ; Said and Rosenberg, 1976), neurotensin (Loonen 
and Soudijn, 1979) and LHRH (Winters, Eskay and Porter, 
1974) are all located primarily in the hypothalamus with 
low concentrations in cortex. 
CCK is present in the hypothalamus in similar concentrations 
to the other hormonal brain peptides but is approximately 
103 times more concentrated in cortex than any other brain 
peptides on a molar basis. Thus, human brains contain 
to 2mg of CCK8 in total whereas other hormonal peptides 
are present in microgram amounts. 
Discreponcies in results exist between different workers in the concen-
trations and hormonal forms of CCK-1 ike peptides in the brain. Rehfeld 
(1978b) showed that CCK33 accounted for 2 - 5% of the total immuno-
reactivity in man and hog brain while Mui ler, Straus and Yalow (1977) 
and Straus and Yalow (1979a) found CCK 33 to be prominent in pig 
brain. Dockray (1980) reported that over 90% of immunoreactive CCK 
in rat cerebral cortex was due to a CCK 8-like peptide and a closely 
related, slightly less acidic, peptide. Only minimal amounts were 
CCK33-like. Straus and Yalow {1979a) have accounted for these 
discrepancies by the existence, in the brain, of converting enzymes 
which if not inactivated early in the extraction procedure wil I 
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result in a larger amount 
be present in vivo while 
of CCK 8 being 
Dockray (1980), 
found, than 
suggests that 
would 
there 
normally 
are 
species differences m the distribution of CCK 33-like material. This 
discrepancy, however, may reflect the disparity that exists between 
different workers on the conditions required for extracting CCK, 
since analysis of the distribution of hormonal forms of CCK m 
brain tissue requires quantitative recovery of the peptide. 
D 3) Distribution of Gastrin Compared to CCK in Nervous Tissue 
Gastrin has always been considered to be stored exclusively in 
specialised endocrine (G) eel Is of the upper gastrointestinal mucosa. 
Uvncis-Wallensten, Rehfeld, Larsson et. al. , (1977), however, showed 
th at G-17 was present in the vaga I nerves of cats, dogs and 
humans whereas CCK-like peptides were totally absent. Gastrin was 
found to be present in nerves of the intestinal wall, predominantly 
in the large and distal smal I intestine in amounts ranging from 16 
273 p mol/g of nerve tissue. These findings suggested that G-17 
may be a new vagal neurotransmitter. In contrast Dockray, Gregory 
and Tracy (1980) have shown CCK 8 to be the predominant immune-
reactive form of G-CCK in the dog vagus, G-17 being of minor 
importance. Further study is needed to clarify this discrepancy. 
Rehfeld (1978c) showed that molecular forms of gastrin closely 
resembling those found m antrum (Rehfeld, Stadil, Malmstrom et. 
al. , 1975) were localised to the neuro and adenohypophysis and 
pituitary stalk whereas CCK was only present in the pituitary stalk 
in very small amounts. Traces of gastrin were found in the hypo-
thalamus but were undetectable by chromatography and absent from 
the rest of the brain. 
These results add a new hormone to the I ist of peptides localised 
to the CNS and gut. The differential distribution of gastrin rn 
relation to that of CCK is of interest in that it occurs in 
regions free of CCK. How and why the common ancestor of 
gastrin and CCK rn antrum and hypophysis develops exclusively 
to gastrin but in jejunum and the remaining brain to CCK is 
an intrigu ing question. 
D 4) Gastrin and CCK in Cerebrospinal Fluid 
Gastrin has been found rn the CSF from neurologically normal 
people at concentrations of 1.5 - 8.0 p mol as compared to CCK 
which ranges from 4 - 55 p mol (Rehfeld and Kruse-Larsen, 1978). 
Using sequence specific antisera and gel chromatography, gastrin 
was found to be present in molecular forms corresponding to 
G-34 and G-17 and CCK to CCK 8 and a fragment corresponding 
to the sequence 25 - 29 of CCK 33 • The similarity of molecular 
forms of gastrin and CCK in brain extracts and CSF supports the 
concept that gastrin and CCK in CSF originate from brain tissue 
26 
and is further supported by the fact that serum gastrin showed no 
correlation with CSF gastrin in the same patient (Rehfeld and Kruse-
Larsen, 1978). 
D 5) Cellular Localisation of CCK and Gastrin 
lmmunocytochemical and immunohistochemical studies, using sequence-
specific antisera have shown CCK and gastrin (G) to be located 
in neurones of the central and peripheral nervous system in a 
specific and differential manner (Table 1. 3). The peptides are 
present in both the neuronal cell bodies and rn terminal processes. 
It is difficult to differentiate between CCK and gastrin though 
evidence suggests that this i mmunoreact i ve 
Alumets, H8kanson et. al. I 1979 ; Innis, 
1979) other forms may also contribute. 
material is CCK 8 (L~ren, 
Correa, Uhl et. al. , 
The distibution observed 
of these 
i) 
ii) 
peptides 
suggests important functions of G-CCK in cortex, I imbic 
structures, including the mesencephalon, the posterior horn 
of the spinal cord and the hypothalamohypophyseal system. 
closely resembles that found by radioimmunochemical studies 
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Table 1. 3 
lmmunoh istochem ical localisation of G - CCK 
Area Cell Fibre Cell Body Author 
Cortex * * 1 ' 2, 4, 5 
Amygdala * * 1 ' 3, 4 
Olfactory bulb * * 1 
Hypothalamus * 3, 4 
Hi ppocampus * * l ' 4, 5 
Paraventricular hypo-
thalamic magnoce 11 u I ar 
nuclei * * l ' 5 
Supraoptic hypothalamic 
magnocel lular nuclei * * 
Circularis hypothalamic 
magnoce 11 u I ar nuc!ei * * 1 ' 5 
Preoptic hypothalamic 
nuclei * * 
Hypothalamic dorso-medial 
nucleus * 6 
Nucleus tractus sol itarii * 
Posterior horn * 1 
Brain stem nuclei * 6 
Posterior hypophysis * 5 
Spinal cord * 4, 5 
Spinal ganglia * 4 
Caudate putamen * 
Accumbens or tuberculum 
olfactorium * 
Limbic structures * 
Medial forebrain bundle * 
A-10, A-9, A-8 region of 
Dahlstrom and Fuxe * 
Substantia nigra * 1 
Mesencephalon central grey * 5 
Medulla oblongata * * 5 
Interstitial nucleus of the 
ventral tegmental decussation * 6 
Ventral periqueductal grey * 6 
Dorsal raphe * 6 
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Authors 
1. Vanderhaeghen, Lotstra, De Mey et. al. {l 980) 
2. Strauss, Mui ler, Choi et. al. (1977) 
3. Hokfelt, Eide, Fuxe et. al. (1978) 
4. Larsson and Rehfeld {l 979) 
5. Loren, Alumets, H8kanson et. al. (1979) 
6. Innis, Correa, Uhl et. al. {l 979) 
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though it is difficult to compare these procedures in 
detoi I because immunocytochemicol and immunohistochemicol 
procedures ore not quantitative (Innis, Correo, Uhl et. al. 
1979). 
D 6) Subcellular Localisation and Release of CCK 
CCK and its COOH-terminol fragments hove been localised to synop-
tosome rich subcellulor fractions of rot cortex (Pinget, Strous and 
Yalow, 1978). The recovery in th is pe I let of 40o/o of the total 
immunoreoctivity in the initial cortical extract is comparable to the 
recovery of other peptides i.e. VIP (Besson, Rotsztejn, Loburthe et. 
al. , 1979 ; Giochetti, Said, Reynolds et. al. , 1977), and SRIF 
(Epelbaum, Brazeau, Tsang et. al. , 1977), which ore also located 
in synaptosomes. Pinget, Strous and Yalow, (1979) hove shown that 
the release of immunoreoctive CCK is increased 200o/o by depolori-
sot ion 
Co++ 
of the plasma membrane with K+ and that this release is 
dependent. Rehfeld, 
showed high K+ evoked a 
Goltermonn, 
significant 
Larsson et. al., (1979) 
++ Co -dependent release of CCK 
from superfused cortical slices from rot brain • 
Release of CCK can be effected under the conditions used to release 
other synaptosomol materials which are known to affect synoptic 
function and it has therefore been suggested that CCK may hove 
a physiological role as a neurotransmitter and/or modulator in the CNS. 
It hos been impossible to study the subcel lular local isoti on and release 
of gostrin from neurones in the CNS due to the low levels of gostrin 
in nerves. Evidence for gas tr in being a neurotransmitter awaits the 
development of a more sensitive gostrin assay. 
D 7) Synthesis of CCK in the Brain 
In order for CCK to be a neurotransmitter it must be synthesised in 
neuronal tissue. 
shown 
Rehfeld, Goltermann, Larsson et. al. (1979) have 
i) an extensive and rapid in vivo 
rat cerebra I cortex. 
biosynthesis of CCK in 
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ii) that a number of molecular forms of CCK are synthesised 
corresponding to a larger component than CCK 39, CCK 39, 
CCK 33, CCK8 
and CCK4 • 
iii) that the large molecular forms are precursors of the smaller 
molecular fragments. 
and thus have shown that CCK I ike other neuropeptides, is synthe-
sised within nerve eel Is. 
E. FUNCTION OF CCK IN THE BRAIN 
E l) Inhibition of Feeding 
Over the past few years it has been suggested that CCK may serve 
as a satiety signal within the CNS and m the periphery, perhaps 
through some type of negative signal from the gastrointestinal tract 
(Schally, Redding, Lucien et. al. , 1967 ; Gibbs, Young and 
Smith, 1973 a, b ; Gibbs, Falasco and McHugh, 1976). It has 
been shown that exogenously administered CCK 33 or CCK8 could 
induce cessation of eating as wel I as the ful I sequence of 11 be-
havioural satiety 11 in rots (Gibbs, Young and Smith, 1973 a,b ; 
Antin, Gibbs, Holt et. al. , 1975; Gibbs and Smith, 1977). 
Blass, Beardsley and Hall (1979) found that CCK exogenously ad-
ministered (10 - 40 u/kg body weight) to neonatal rat sucklings 
lowered milk intake at the age when the established specific 
inhibitors of ingestion first became effective and did not reduce 
intake at a time when other feeding inhibitors were not effective. 
CCK 8 specifically decreased food intake in a dos
e-related manner 
when injected continuously into the lateral cerebral ventricles of 
sheep that had been deprived of food for 2, 4, 8, and 24 hours. 
This effect was not related to water deprivation (Della-Ferra and 
Baile, 1979). Pentagastrin was found to decrease feeding in the 
2 hour group but only at a much higher dose and resulted m 
abnormal behaviour. This could be explained by the similarity in 
the COCH-terminal pentapeptide sequence of the two peptides. 
Secretin had no effect on food intake. Rats appear to be less 
sensitive than sheep to the CNS-mediated inhibition of feeding by 
CCK 8 or pentagastrin. 
Only in rats deprived of food for 4 
hours before intraventricul ar injection at a higher dose range 200 -
300 p mol/kg was food intake found to be decreased (Del la-Ferra 
and Baile, 1979). 
Mueller and Hsiao (1979) working with rats deprived of food for 
0, 5, 19, 48 and 92 hours showed that synthetic CCK8 produced 
a dose-related suppression of I iquid diet, lasting 105 min, far 
beyond the 15 min half I ife of CCK and that th is onset of 
satiety was dose-related. The effect of CCK on food-sated rats 
was observed by administering hyperton ic sol ine before presentation 
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of a I iquid diet. 
content. 40 u/kg 
They wil I drink the 
CCK suppressed intake 
I iqu id diet for the water 
by 76°/o which was shown 
not to be due to thirst. 
CCK, thus seems to fulfil I one of the criteria for a short-term 
satiety signal and that is that the satiety inducing effect of CCK 
should 
,' 
interact in a consistent and adaptive manner with the state 
of nutritional deficit of the organism (Mueller and Hsiao, 1978). 
CCK 33 and CCK 8 
have been shown by Lorenz, Kreielsheimer and 
Smith (1979) to cause satiety in sham fed rats when slowly infused 
intravenously. Thus satiety did not depend upon high circulating 
levels of CCK that can occur after intravenous or intraperitoneal 
injections. Gastrin, secretin and GIP also released by ingested 
food stimuli had no effect on sham feeding thus demonstrating the 
specificity of CCK for satiety. It has been reported, in conflict 
1
-"tt earlier reports (Anika, Houpt and Houpt, 1977 ; Houpt, Anika 
and Wolff, 1978) that bilateral subdiaphragmatic vagotomy markedly 
reduces or abolishes the satiety effect of CCK 33 and CCK8 
(Lorenz and Goldman, 1978 ; Smith and Cushin, 1978) suggesting 
that the vagus nerve forms the I ink between the visceral site of 
action and the brain. 
E 2) Affect of CCK on Different Nutritional States 
Straus and Yalow (1979b) have demonstrated that obese (ob/ob) mice 
with hyperphagia have significantly lower cerebral cortical concentrations 
of CCK than their lean I itter-mates and other normal mice. 
Schneider, Monahan and Hirsch (1979) m contrast, using the 
same extraction procedure, assay system and source of mice 
found no difference between ob/ob mice and their lean litter-
mates. 
Conflicting data also exists between these two groups on the 
levels of CCK m the brain m fasted and fed mice. Schneider, 
Monahan and Hirsch (1979) showed that extremes in nutritional 
status and feeding behaviour had no apparent effect on the 
concentrations of CCK in the major anatomic regions of the 
brains of rats and mice. 
to severe early malnutrition, 
highly palatable diets causing 
lesioning of the ventromedial 
Different groups of rats were subjected 
deprivation 
hyperphagia 
hypothalamus 
of food for 72 hours, 
and surgical or chemical 
causing hyperphagia. 
Al I groups showed no alterations in levels, molecular forms or 
regional distribution of brain CCK from those found in control 
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animals. In contrast Straus and Yalow (1980) found that iCCK was 
accutely responsive to 
2 - 5 days showed a 
changes in feeding 
reduction in iCCK 
patterns. Mice, 
+ from 274 - 2ng/g 
fasted for 
to 133 ~ 
6ng/g and concluded that acute fasting markedly suppresses cortical 
iCCK. 
Straus and Yalow (1979b ; 1980) found no difference in brain weights 
between ob/ob mice and their lean litter-mates and fasted and fed 
mice. Schneider, Monahan and Hirsch (1979), however, found that 
at every age studied the ob/ob mice had significantly lower brain 
weights than their lean litter-mates. Th is is in agreement with 
other workers (Margules, Moisset, Lewis et. al., 1978; Van der 
Kroon and Speijers, 1979 ; Rossier, Rogers, Shibasaki et. al. , 1979). 
The method of analysis employed permits reproducible quantitative 
determinations of the amount of peptide per gram of tissue. Such 
a system, however, depends on the existence of significant changes 
in levels of peptides in an entire region of brain, although a 
more refined dissection technique may show local changes. In the 
circumstances where experimental animals had lower brain weights 
(undernourished large-I itter rats, Zucker fatty rats and ob/ob mice) 
than controls
1 
the total brain content of CCK would have been 
correspondingly reduced whereas the amount per gram of tissue was 
not. Whether concentration of brain CCK is more physiologically 
relevant than total brain content of CCK remains to be determined. 
It is also 
changes in 
(Schneider, 
possible that 
the synthetic 
Monahan and 
CCK is unchanged as 
and degradative rates 
Hirsch, 1979). In 
a resu It of para 11 e I 
of the peptide 
addition both groups 
were looking at static levels rather than dynamic alterations in 
function. If the ob/ob genotype has reduced levels of CCK it 
suggests that CCK 8 may play a role in the genesis 
of obesity 
(Straus and Yalow, 1979b). 
E 3) Affect of CCK on Pituitary Hormone Release 
lntraventricular injections of CCK 8 into conscious ovarectomised rats 
was found to suppress thyroid stimulating hormone (TSH) and leutei-
nizing hormone (LH) but to elevate prolactin (PRL) and growth 
hormone (GH). Plasma follicle stimulating hormone (FSH) was not 
of CCK 8 caused no significant 
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altered. 
changes 
dose but 
in 
Intravenous injections 
GH, TSH and FSH. 
th is was thought to be 
PRL was 
a stress 
elevated by 
effect; PRL 
the 
being 
low 
rapidly 
e I evated by stress. Control injections of saline intravenously or 
intraventricularly did not modify plasma hormone levels (Vijayan, Samson 
and McCann, 1979). These results indicate that CCK can alter 
pituitary hormone release via a hypothalamic action and suggests that 
it may act as a neurotransmitter or neuromodulator control I ing the 
release of hypothalamic releasing and/or inhibiting hormone. Support 
for this concept came from Morley Melmed, Briggs et. al. , 
(1979). They showed that CCK 8 released GH from incubated rat 
anterior pituitary quarters and from cultured GH
3 
pituitary tumor cells 
and that in the GH 3 eel I I ine CCK 8 
reversed the inhibitory effect 
of SRIF on GH release. Thus it was suggested that CCK 8 was' an 
endogenous GH releasing factor. 
E 4) The Target the CCK Receptor 
If CCK is involved in the regulation of brain functions, then brain 
cells should possess CCK receptors analogous to those for other 
polypeptides. Saito, Sankaran, Goldfine et. al. 
' 
(1980) using 
125 
CCK, CCK analogue which has full biological I-Bolton-Hunter a 
activity, have measured specific CCK binding sites m particulate 
fractions of rat brain, known to contain iCCK. The brain CCK 
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receptor was shown to interact with CCK 33 , CCK 8 and CCK 4 , three 
of the different molecular forms of CCK found m the brain. The 
concentration and distribution of the receptor sites closely resembled 
that of iCCK determined by RIA (Table 1.3). 
It has been postulated that CCK is involved in satiety. McLaughlin 
and Baile (1979) found that obese Zucker rats were less sensitive 
to intraperitoneal injections of CCK (20 u/kg), than their lean I itter-
mates, to inhibition of feeding after a six hour fast. Th is suggests 
that absolute levels of CCK may be unimportant as opposed to 
differences in sensitivity at the receptor sites. 
Zetler (1979) showed that the intestinal actions of CCK 8 could be 
competitively antagonised by morphine, p-endorphin and the enkephalins. 
The receptors for these two groups of peptides are thought to be 
different, antagonism occurring by a specific physiological interaction. 
This and their distribution in gut and brain suggests that these two 
groups of peptides interact on both myenteric and CNS receptors 
and are involved in the regulation of intestinal mot ii ity. Evidence 
showing that genetically obese mice have elevated levels of p-
endorphin (Margules, Moisset, Lewis et. al. , 1978) and low levels 
of CCK (Straus and Yalow, 1979b) suggests that these two groups 
of 
the 
peptides 
amino 
interact to bring about 
4 acid sequence of (Trp , 
of CCKT 
In addition satiety regulation. 
5 Met ) an enkephalin analogue resembles 
Sch ii ler, Lipton, Horrobin et. al. , the NH 2-terminal sequence 
(1978) have shown that unsulphated CCK7 has an affinity for the 
opiate receptor in the micromolar concentration range though as yet 
this has no known physiological significance as unsulphated CCK has 
not been found in brain (Dockray, 1980). Further studies on the 
relations between 
action wil I help 
brain function. 
brain and CCK levels, 
explain the nature of 
CCK receptors and 
polypeptide regulation 
CCK 
of 
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SECTION II Measurement of Cholecystokinin 
A. DEVELOPMENT OF A RADIOIMMUNOASSAY FOR CCK 
Three factors made the development of a sensitive and reliable 
radioimmunoassay for CCK difficult 
1. 
2. 
3. 
Conventional isotope label ling techniques involve oxidation. 
This results in oxidation of the three methionine residues 
of CCK in positions 9, 28 and 31 which are crucial 
for the preservation of bioactivity and immunoreactivity 
(Mutt and Jorpes, 1971 ; Mutt, 1964). 
The common COOH-terminus of gastrin and CCK renders 
many antisera raised against CCK unspecific. 
Pure CCK is not readily available. 
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Go, Ryan and Summerskill (1971) ; Harvey, Dowsett, Hartog et. al. , 
125 (1973) used I-G-17 as radioactive tracer for measuring CCK by 
radio immunoassay. Rehfeld (1978a) used 1251 hydroxyphenyl propionic-
acid succinimide ester (Bolton and Hunter, 1973) which resulted in 
a tracer which displayed minimal preparation damage, an immuno-
reactivity indistinguishable from that of native labelled CCK with 
al I the antisera employed and a high specific radioactivity. The 
quality of the tracer compared well with high quality monoiodinated 
tracers in other peptide radioimmunoassay systems (Stadil and Rehfeld, 
1972 ; Damkjaer, Jprgensen and Giese, 1971). 
A modified method of iodination of CCK to 1251 Bolton-Hunter (BH) 
reagent resulted m the production of a stable, high specific activity 
radio-iodinated CCK. The tracer thus prepared was biologically active; 
125
1-BH-CCK binding to specific receptor sites on isolated pancreatic 
acini (Sankaran, Deveney, Goldfine et. al. , 
this tracer it is now feasible to study CCK 
assay and radioreceptor assay (Gorden, Gavin, 
1979). Thus using 
by bioassay, immuno-
Kahn et. al. , 1973). 
Antisera of high titres and avidities, raised toward partially purified 
porcine CCK 33 (either free or coupled to bovine serum albumin), 
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were found to react with different regions along the chain of CCK 33 
(Rehfeld, 19780). Thus it has been shown that CCK displays a 
high immunogenicity generating antisera of high titers and binding 
off in ities and that sensitive radioimmunoassays for CCK can be 
established (Rehfeld, 19780). Postulates of CCK being a poor 
immunogen are thus incorrect. 
B. FRACTIONATION OF iCCK 
Straus, Malesci, Pinget et. al. , 0979) have shown that it is 
possible to distinguish between the basic precursor peptides CCK 33 
and its variant CCK 39 and the
ir (OOH-terminal 12 and 8 amino 
acid fragments in plasma and tissue extracts by adsorption of the 
peptides to silica and talc. CCK 39 and CCK 33 
are quantitively 
adsorbed whereas CCK 12 and CCK 8 
are not detectably adsorbed by 
either. 
Prior to this discovery intact CCK and CCK fragments have been 
distinguished either by radioimmunoassay or separation on Sephadex 
G-50 (sf). 
C. RADIOIMMUNOCHEMICAL QUANTITATION OF GASTRIN AND CCK 
Radioimmunoassays for gastrin and CCK have mainly been developed 
for the smaller molecular forms, CCK 8 and G-
17 (Rehfeld, 1978a). 
The lack of knowledge about the extent to which each assay 
measures the larger molecular precursors and the fact that pure 
CCK 's from different species are not readily available as radio-
immunoassay standards hinders the quantitative determination of the 
different forms. De Magistris and Rehfeld (1980) have developed 
an enzymatic procedure for determining the extent of binding of 
large precursor forms to antisera raised against the small hormonal 
forms and al lows accurate quantitation of the different molecular forms 
of gastrin and CCK in biological fluids. 
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CHAPTER T W 0 
MATERIALS AND METHODS 
INTRODUCTION 
This section covers al I general methodology and more specific tech-
niques used in the study. Details of experimental procedures will 
be described in full in the relevant chapter. 
In this chapter the tissue dissection of the rot brain IS described 
along with the technique for extracting iCCK 8 
from the regional 
areas of the brain re levont to the study i cerebral cortex, hypo-
thalamus, thalamus, striotum, brain stem, cerebellum and spinal cord. 
Using the some extraction technique iCCK 8 was
 found to be present 
in synoptosomes prepared from rot cerebral cortex, hypothalamus, tholo-
mus and striotum. The preparation of these synoptosomes, which were 
subsequently used for in vitro incubation experiments, will be described 
in detail here. In addition, techniques used for determining the 
viability and purity of the in vitro tissue preparations, measurement 
of protein, oxygen consumption, lactate dehydrogenose activity and 
electron microscopy wil I be described. And finol ly the rodioimmuno-
assay used to measure the amount of CCK 8 and the criteria used t
o 
characterise the material will be outlined. 
A. ANIMALS 
under conditions of Adult mole 
temperature 
I ight-dork 
Long-Evans 
(18 - 20°C) 
rots 
and 
(200 - 250g) were housed 
humidity (40 - 60%) with 
cycles and allowed free access to commercial 
alternating 12 hour 
rot pellets (Epol 
Foods, Cope Town) and water, were used in all studies. Rots were 
decapitated between 09h00 and 1 OhOO, the brains removed to on ice 
troy and dissected. 
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B. DISSECTION OF BRAIN AREAS 
The brain was dissected into cerebral cortex, hypothalamus, thalamus, 
striatum, spinal cord, cerebellum and brain stem as described by 
Brownstein, Arimura, Sato et. al. (1975). The vertebral canal was 
dissected open, the spinal cord exposed and removed. 
i) The first cut was at the level of the optic chiasm 
through the brain 1n the coronal plane. 
ii) The second cut 3mm anterior to the first (rostral). 
iii) The third cut 3mm posterior to the first (caudal). 
iv) The rostral slice was dissected into striatum and 
cortex. The cortex was defined by the corpus 
col losum and the striatum by the corpus col losum 
and the lateral ventricles. (Fig. 2. 1) 
v) The caudal slice was dissected into hypothalamus, 
thalamus and cortex. The hypothalamus being defined 
laterally by the amygdala and extended dorsally from 
the top of the brain to the top of the third ven-
tricle. The hi ppocampus and internal capsule defined 
the thalamus which was removed from the slice. 
(Fig. 2. 2) 
vi) The cerebral cortex from both slices were pooled. 
C. TISSUE EXTRACTION 
C 1) In boi I ing water 
Immediately after dissection the tissue was put into 25ml glass scintil I-
at ion vials and weighed on a top loading balance (Sartorius 1205 MP, 
readability o. 001 g) and snap frozen in liquid nitrogen (-196°C). The 
tissue was transferred from the liquid nitrogen into 3ml of boiling 
distilled water and placed in a boiling water bath for 20 min. After 
boiling the liquid was decanted, (the tissue kept for protein estimation) 
made up to 5ml with distil led water and centrifuged at 1 .7 x 103 g for 
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fig 2. 1 
cc 
"' 
Rostro\ s\'ice of rot brain 
spo septum and preoptic area 
\v \atero\ ventric\e 
st striotum 
cc corpus co\\osum 
cerebra\ corte,< C)( 
41 
Fig 2.2 
ex 
Caudal slice of rat brain 
h hypothalamus 
a amygdala 
IC internal capsule 
cc corpus callosum 
3v third ventricle 
th thalamus 
hi hippocampus 
ex cerebral cortex 
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30 4oc min at to remove any extraneous pieces of tissue. 
Following centrifugation the supernatent was decanted, frozen, lyo-
philised and stored at -20°C until assayed. The capped vials 
were reweighed and the tissue weights recorded. 
C 2) In acetic acid 
Exactly the same procedure was used except after boiling in water 
for 20 min, 3ml of 0.5 M acetic acid was added to the 3ml of 
boiling distil led water In the tubes to give a final concentration 
of 0.25 M acetic acid and boiled for a further 10 min. 
The lyophi I ised samples were resuspended in sodium barbital buffer 
pH 8.4 and appropriately diluted on the day of assay. All samples 
were assayed with an antigastrin G-2 antiserum which had 7°/o cross-
reactivity with CCK 8 • (Chapter Two) 
The tissue samples were solubilised by homogenising in 2ml of 0.5°/o 
w/v sodium deoxycholate. The homogenates were appropriately diluted 
1n 0. 5°/o w/v sodium deoxycholate and protein estimation was performed 
according to the method of Lowry, Rosebrough, Farr et. al. (1951). 
D. PREPARATION OF SYNAPTOSOMES 
Immediately after decapitation the 
f d · 4°C. trans erre to an icy tray, 
brains of male Long-Evans rats were 
Synaptosomes were prepared from 
cortex, hypothalamus, thalamus and striatum according to the method 
of Gray and Whittaker (1962) as modified by Bennett and Edwardson 
( 1975). Thalamus and striatum were dissected as previously described, 
the cerebral hemisphere was removed as one piece (Fig. 2.3) and the 
hypothalamus was removed as a block 1 mm deep bounded by the optic 
ch iasm, lateral hypothalamic fissures and mami I lary bodies. 
In each experiment brain areas from 5 - 10 rats were pooled and homo-
genised In 10 volumes (w/v) ice-cold 0.32 M sucrose (Miles Laboratories). 
A glass homogeniser with a perspex pestle and a clearance of 0.25mm 
was used for 13 passes at a speed of 900 revolutions per min 
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Fig 2.3 
Cortex of the rat brain 
(Bennett and Edwardson, 
was centrifuged for l 0 
1975) (Fig 2. 4). 
3 
The homogenate 
gerated centrifuge 
nuclei and debris 
min at l X lQ g 
(Du Pont 
(Pl) was 
Instruments). 
in a Sorval I refri-
A pellet containing 
aspirated using a wide-bore 
4 
at 2 x 10 g. The pellet 
discarded and the supernatent (Sl) 
pipette and centrifuged for 20 min 
(P2) consisting of myelin, synap-
tosomes and mitochondria was resuspended in + 5 ml 0. 32 M 
sucrose, carefully applied to a discontinuous sucrose density 
gradient consisting of 10ml of 1.2 M sucrose and 12ml of 
O. 8 M sucrose and centrifuged for 90 min at 7. 5 x 104 g 
(Beckman ultracentrifuge model L5-65, SW 25. l rotor). Myelin 
sedimented at the 0.32 M - 0.8 M interface, synaptosomes at 
the O. 8 M - l. 2 M interface and mitochondria at the bottom of 
the tube, confirmed by electron microscopy, enzyme activities and 
oxygen consumption. The myelin and synaptosome layers were 
removed separately using a wide-bore pipette and the mitochondrial 
pellet resuspended in 0.32 M sucrose (Fig 2.5). 
Samples from each of these layers were extracted for CCK8 as 
previously described. 
In order to obtain a synaptosomal pellet for in vitro incubation 
studies the 0.8 M - 1.2 M layer was slowly diluted 2.2 x volume 
with ice-cold triple distilled deionised water to give approximately 
a 0.45 M sucrose synaptosomal 
for 20 min at 4 x 104 g at 
resuspended and used according 
suspension. This was 
0 4 C. The synaptosomal 
to the protocol of the 
E. MEASUREMENT OF PROTEIN CONCENTRATION 
centrifuged 
pellet was 
experiment. 
Protein estimation was performed according to the method of Lowry, 
Rosebrough, Farr et. al. , (1951). 
Reagents 
A 2o/o w/v Na2co3 in 0. l N NaOH. 
B 0. 5o/o w/v CuSO 4 • 5H20 in l o/o w/v potassium 
sodium tartrate. 
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Fig 2. 4 
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to 
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a smooth precision-
maintain temperature 
Fig 2. 5 
Homogenise tissue in 
0 · 32M sucrose c 101wtv > 
l Centrifuge 1 x 103 g 
for 1om1n 
Centrifuge 20x 103g for 20 min 
Mitochondrial pellet in 0·32Msucrose 
0·8M sucrose 
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1 Centrifuge 75 x ,o3g for 90 min 
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! 
Resuspend pellet in 
appropriate experimental 
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''i.,.. 
Preparation of purified synaptosome fraction from homogenates of 
rat brain 
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Method 
Results 
C Before use 50ml of reagent A was mixed 
with 1ml of reagent B. 
D Folin-Ciocalteu reagent (Merck, Darmstadt) 
E 
2 
3 
with distil led water. diluted 
Standards purified crystal I ine bovine serum 
albumin (BDH) dissolved in 0. 154 M NaCl, 
containing 0.5% w/v sodium deoxycholate 
(Merck), to give solutions containing 360, 
240, 160, 120, 80 and 40 JJglml. 
Al I assays were carried out in triplicate as 
follows 
0.2ml of standard or sample. 
1.0ml of reagent C, mixed and allowed to 
stand at room temperature. 
After 10 min 0. l ml of the fulin-Ciocalteu 
reagent (solution D) was added and mixed. 
4 After 30 min at room temperature absorbance 
was read at 750nm by means of a Zeiss PMZD 
spectrophotometer. 
Absorbance was I inear over the working range 
(40 - 360 µglml). 
Reproducibi I ity lnterassay coefficient of variation was 2.2% 
(n = 9). 
F. MEASUREMENT OF LACTATE DEHYDROGENASE ACTIVITY 
Johnson, 1960 
L - lactate NAD ox idoreductase, EC l • l • l • 27 
The synaptosome fraction of the brain is rich in occluded lactate 
dehydrogenase (LOH) activity (Marchbanks, 1967). The plasma 
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membrane of the synaptosome is destroyed when treated with a 
non-ionic detergent (Triton X - l 00) thus releasing the LDH occluded 
within the synaptosome. The amount of LDH released was mea-
sured using the fol lowing technique 
Principle 
Reagents 
Procedure 
Pyruvate + NADH ~ lactate + NAD 
The oxidation of NADH is observed at 340nm 
and in the absence of interfering reactions 
is a direct measure of the reduction of 
pyruvate to I act ate (Kornberg, 1955). 
0.01 M 
0.002 M 
0.15 M 
pH 7.4 
Na Pyruvate (Hopkins and Williams Ltd) 
NADH (Sigma) in l % NaHC03 
Triethanolamine HCI (Sigma) adjusted to 
l 0% w/v Triton X - l 00 (BDH) 
Reagents were added in the fol lowing sequence 
5ml Na Pyruvate 
2 5ml NADH (freshly prepared) 
3 50ml Triethanolamine buffer 
4 90ml distilled water 
3ml of this mixture was added to 4ml glass cuvettes (Beckman) 
with a 1cm lightpath. Smal I volumes of sample (5, l O or 
20 µI) were added to the cuvette and contents mixed. The 
change in optical density (O.D.) was determined at 340nm (change 
E340) · I m,n at 25°C by in over approximate y means of a 
Uni cam SPl 700 unltraviolet spectrophotometer (A). 300pl of Triton 
X - l 00 was now added, the cuvette contents mixed, and optical 
density changes noted over a further 
Results 
min (B). 
i) A represents LDH activity not occluded with-
in synaptosomes. 
ii) B is the total LDH activity In the sample 
after disruption of the synaptosome by detergent. 
iii) B A is occluded LDH activity. 
Definition of unit and specific activity one unit of enzyme is 
defined as that amount which causes an initial rate of oxidation 
of lµmol of NADH per min. Specific activity is expressed as 
units per mg protein (Kornberg, 1955). 
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specific activity = 6 0. D. / 
-----~---
min X 
6.22 mg protein 
where 
6 -1 6.22 x 10 sq cm x mole is the extinction coefficient of 
the pyridine nucleotide at 340nm (Horecker and Kornberg, 1948). 
G. MEASUREMENT OF OXYGEN CONSUMPTION USING THE WARBURG 
TECHNIQUE 
Umbreit, 1949 Laser, 1961. 
Principle At constant temperature and constant gas volume 
any changes In the amount of a gas can be 
measured by changes 1n its pressure. 
The apparatus consists of a detachable flask, containing the tissue 
suspension, attached to a manometer containing a I iquid of a 
known density. The flask IS immersed b h at 37oc a water at 
and shaken between readings to promote a rapid gas exchange 
between the fluid and gas phase. 
meter 1s assumed to be constant. 
The temperature of the mono-
A reference point on the closed 
side of the manometer (usually 150 or 250mm) is chosen and the 
liquid in the closed arm of the manometer 1s always adjusted to 
this point before recording pressure changes. The principle of 
the method 1s to hold the gas and fluid volumes constant and 
to measure the decrease or increase in pressure when one gas 
alters its amount. 
If the gas volume of the flask, the volume of fluid in the flask, 
the temperature of ope rat ion, the gas being exchanged and the 
density of the fluid in the manometer are known it is possible to 
derive a flask constant with which one can convert mm pressure 
change into ,-,I gas consumed. 
i) Calulation of flask constant (k) 
Vg 
k = 
273 
T 
p 
+ 
0 
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where Vg = volume of gas phase In flask including 
connecting tubes down to the manometer 
reference point, 
vf = volume of fluid In vessel, 
p = standard pressure (760mm Hg or 10 000mm 
0 
Kreb's fluid), 
T = temperature of water bath In absolute 
degrees (= 273 + temperature in 0°C), 
= solubility in reaction liquid of gas in-
volved. 
ii) Calculation of amount of gas exchanged (x) 
X = hK 
where X = amount of gas exchanged (JJ I) at o0 c and 
760mm Hg pressure, 
h = alteration In reading on open arm mono-
meter (mm), 
k = flask constant 
G l) Use of the Warbur~ instrument for the measurement of 
respiration of living cells 
In most living cells the bi product of 02 consumption is release 
of CO2 which can be absorbed by alkali rendering the CO2 pressure 
In the air to zero within the limits of rre asurement. Thus the 
change noted on the manometer is a measure of 02 utilisation. 
The uptake of 0 2 in mm is calculated by subtracting the initial 
reading from al I subsequent readings (total uptake method). A 
thermobarometer, consisting of a flask containing only water, 1s 
used as a measure of the changes in atmospheric pressure and 
temperature of the water bath. The readings are corrected for any 
changes occuring during the experiment. The product of the uptake 
in mm (x) and the flask constant (k) for the conditions employed 
gives the /JI 0 2 consumed. 
H. 
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Method 
i) Al I the manometer joints were greased with inert 
silicone vacuum grease. 
ii) 3ml of Kreb's Ringer's Phosphate buffer (as descibed 
rn chapter four) was added to the flask. 
iii) 2 pellets of KOH were added to the central well. 
iv) Hypothalami or a suspension of cortical synaptosomes 
were added to the fl asks. The flasks attached 
to the manometer and placed in a shaking water 
bath at 37°C. 
v) 10 - 15 min was al lowed for equ i I ibrat ion of the 
manometers before the fluid was adjusted to the 
reference point (150mm) on the closed side of the 
manometer with the stop-cock open. 
vi) Stop-cocks were closed and readings begun. 
G 2) Calculation of 0 2 consumption 
pmol 0 2 consumed / hour g tissue = 
hk 
22. 4 x wet weight (g) 
ELECTRON MICROSCOPIC EXAMINATION OF SUBCELLULAR FRACTIONS 
FROM THE SYNAPTOSOME PREPARATION 
Myel in, mitochondria and synaptosomes prepared by differential centri-
fugation, as previously described, were gently resuspended in 3.0ml 
of ice-cold 4% w/v glutraldehyde and allowed to fix for 60 min 
at 4°C. The fractions were then washed 3 times in 0. l M 
phosphate buffer, pH 7. 2 and stored for 24 hours at 4°C in 
0. l M phosphate buffer. 
w/v osmium tetroxide 
embedded rn standard 
tissue was sectioned 
Pel lets were subsequently fixed in l % 
for 15 
Spurr's 
at 500 A 
min, dehydrated in acetone and 
resin at 70°C for 24 hours. 
intervals on an unltramicrotome 
The 
and 
stained with uranyl acetate (saturated solution) and 0. 2% w/ v lead 
citrate. The resultant sections were examined with the use of a 
Siemen's transmission electron microscope. 
Electron microscopy was performed by J Horne. 
I. CHROMATOGRAPHY 
Extracts from brain areas, discontinuous gradient fractions, released 
material from incubated synaptosomes and incubated 
were lyophil ised, diluted in 
pH 8.4 and applied to a 
1 ml of sodium barbital 
hypothalami 
buffer O. 05 M 
Sephadex G-50 superfine (sf) column 
(150 x 1.5cm). The column was equ i I ibrated In and eluted with 
50 mM 
azide, 
sodium barbital buffer pH 8.4, 
at a flow rate of l 6ml/h at 
containing 0. 01 o/o sodium 
4°C. 1. 6ml fractions 
were collected. The column was equilibrated with blue dextran, 
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cyanocobalamine, SHG-17-1, CCK 33, CCK 8 pentagastrin and potassium 
iodide. 
J. RADIOIMMUNOASSAY OF CCK 8 
lmmunoreactive CCK 8 was measured by radioimmunoassay using two 
different antisera, either CP6 or G-2. The reference standard 
used for both radioimmunoassays was synthetic CCK 8 (Squibb, batch 
no. NN014NB) which was reconstituted in ammonium hydrogen 
carbonate (0. 25 M) and stored at 1 mgl ml concentration. The protocol 
for each assay is described below and the antiserum used to measure 
the amount of immunoreactive CCK 8 wil I be specified in each 
chapter. 
J 1) Radioimmunoassay using the G-2 Antiserum 
CCK 8 was measured by radioimmunoassay using the G-2 antiserum 
which was raised by the immunization of 
gastrin (SHG) 2-17. The label used was 
from CEA Sorin, France, with a specific 
a rabbit with human 
125 
1-S HG-17-1 purchased 
activity of 1000 - 1300 
fJCi/µg. The assay procedure was as follows To each tube was 
added 700 fl sodium barbital buffer (0.05 M), pH 8.4, 100 JJI 
unknown sample or CCK
8 
500 000) and 100 µI label 
were al lowed to incubate 
standard, 100 pl antiserum (diluted 
(opproximately 
for 24 hours 
10 000 cpm). The tubes 
at and free antigen 
was separated from antibody bound antigen by precipitation with 
500 ,_,I of 4% charcoal treated with dextran (0.4%) and centri-
fugation. 
counts. 
absence 
.:: S EM) 
+ SEM). 
In 
of 
and 
The precipitates were counted for 2 min or 10 000 
6 consecutive 
added unlabelled 
the non-specific 
assays the mean binding in 
+ 50.1% - 0.73% 
+ 
CCK 8 was 
binding was 1.8% - 0.2% 
the 
(mean 
(mean 
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The ID 50 for the 
+ 
dose response curve was 836 °"!: 37 pmol/1 
(mean - S EM) n 
of variation was 17.2% 
(Fig 2 .6). 
(n = 6) at 
The interassay coefficient 
the mid-point of the curve 
and the intra-assay coefficient of variation was 6.8% (n = 10). 
The lowest detectable dose of CCK 8 was 50 pmol/1. The 
antiserum crossreacted with CCK 8 7% (courtesy of Mr Luciano, 
Squibb Laboratories); CCK 33 0.7% (courtesy of Dr V Mutt, 
Karol inska Institute, Stockholm) and CCK 4 0.4% (courtesy of Dr 
J Morley, Imperial Chemical Industries, London) when compared 
with non-sulphated heptadecapeptide gastrin (G-17-1) (courtesy of 
Dr Morley). 
J 2) Radioimmunoassay using the CP6 Antiserum 
CCK 8 was measured by radioimmunoassay using the CP6 antiserum 
which was rabbit with CCK8 
( courtesy of 
jugated to 
raised by the immunization of a 
Mr Luciano, Squibb, Princeton, 
whelk haemacyanin (Sigma). The 
N. J. , U. S. A. ) con -
label was 1251-SHG-17-I 
purchased from CEA Sorin, 
1 300 pC i/ pg • The assay 
was added 700 pl sodium 
unknown sample or CCK 8 
France, 
procedure 
barbital 
standard, 
with a specific 
was as follows 
buffer (0.05 M), 
100 /JI antiserum 
activity of 1000-
To each tube 
pH 8. 4, 100 1-11 
(di luted : 1500) 
and 100 fJI label (approximately 10 000 cpm). The tubes were 
al lowed to incubate for 48 hours at 4°C and free antigen was 
separated from antibody-bound antigen by precipitation with 500 pl 
4o/o charcoal treated with dextran (0. 4%) and centrifugation. The 
tubes were counted for 2 min or 10 000 counts. In 10 consec-
utive assays the mean binding in the absence of added unlabelled 
r·. 
' . J 
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Fig 2. 6 
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Displacement of 
125 
-I-SHG-17-1 bound to the G-2 antiserum by 
increasing amounts of unlabelled CCK 8 expressed as o/o bound. 
The mean "!: SEM of 6 consecutive immunoassays are shown. 
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CCK
8 45.2 
+ 1. l o/o (mean + SEM) and the non-specific was -
binding 9o/o + O.lo/o (mean + SEM). was - -
The ID50 for CCK 8 307 
+ 14.7 pmol/1 (n 6) (Fig 2 .7) was - = 
+ whilst the lowest detectable level was 30 
- 0.5 pmol/1 (n = 6). 
The interassay coefficient of variation at 360 pmol/1 was l 3.7o/o 
and at 1250 pmol/1 was 22. l o/o (7 assays) and the intra-assay co-
efficient of variation was 8. 3o/o (n = 8). The antiserum cross-
reacted with synthetic human gastrin (SHG) 17-1 270o/o (courtesy of Dr J 
Morley, Imperial Chemical Industries, England) ; natural human gastrin 
(NHG) 
CCK4 
17-11 
o. l o/o 
305o/o ( courtesy 
(Dr Morley) and 
of Dr J Walsch, Cure, Los Angeles) 
CCK 33 · 79o/o ( courtesy of Dr V Mutt, 
Karol inska Institute, Stockholm) as compared to CCK 8 • 
Crossreactivity with VIP, met and leu enkephal in, substance P, 
neurotensin, TRH, insulin, glucagon, bombesin, SRIF, LHRH and 
PRL was less than O. 001 o/o with both the G-2 and CP6 antisera. 
In addition the test substances in the concentrations used, did not 
inhibit binding in the assays. 
Thus these hybrid assay systems, although crossreacting with other 
gastrin peptides, were relatively specific for CCK 8 in view of their 
low crossreactivity with other (CK-like peptides and the low concen-
trations of gastrin as compared to CCK
8 in the brain (Rehfeld, 
1978 b,c). 
K. PARALLELISM 
If the amount of immunoreactivity tn an unknown sample falls I inearly 
with dilution and is para I lei to the synthetic standard inhibition 
curve it suggests identity between the unknown sample and the syn-
thetic standard. 
Method 
Brain extracts and released material from incubated hypothalami and 
synaptosomes were serially diluted in assay buffer and compared to 
the inhibition curves of G-17 and CCK 8 standards. The results 
were analysed by linear transformation of the inhibition curves (Feldman 
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Fig 2 .7 
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and Rodbard, 1971) to 
binding to antibody (B) 
Bo = 1251G-17 binding 
labelled CCK 8 • 
log it B /Bo = log 
e 
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enable comparison of slopes. 
1251G-17 
was expressed as log it B/Bo where 
to antibody in the absence of un-
Logit B/Bo was plotted on the ordinate against log dose or dilution 
on the abscissa and the data subjected to linear regression analysis, 
al lowing the regression coefficient (b) and correlation coefficient (r) 
of each line to be calculated. 
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Statistical Methods 
The Mean 
X = :;E X 
n 
where X = the observations 
::E = the sum of 
n = the number of observations 
2 Standard Deviation 
S.D. = 
~x - ;.J2 
n - l 
where n ~ 30 
3 Standard Error of the Mean 
SEM = S.D. 
Tn 
4 Coefficient of Variation 
= S .D. x 100 
-X 
5 Least Square Regression Line 
A I ine of the form y =a+ bx was fitted to pairs 
of figures (xl' y l)' (x2' y2) .•.•..•.•.. (x' y n) 2 n 
when a = ( ::E z'.) ( :;Ex ) (:;E x) (:;Exz:) 
n:;E X 
2 (::E xl 
b = n ::E z'. (:;Ex) ( ::E z:) 
n :;Ex 2 (::E xl 
6 Correlation Coefficient 
r = (::Ex) (:;E ) 
7 
8 
Comparison of the slope of the regression I ines was 
by the analysis of covariance (Snedecor and Cochran, 
1967). 
Mean Integrated Response (Richardson, Welsch, Hicks 
et. al. , 1976). 
Numbers 7 and 8 were calculated using programmes 
developed for the specific purpose by Dr L J K laff, 
Department of Medicine, Medical School, Cape Town. 
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CHAPTER T H R E E 
CENTRAL NERVOUS SYSTEM DISTRIBUTION OF CHOLECYSTOKININ 
OCTAPEPTIDE 
INTRODUCTION 
The discovery of several hypothalamic-releasing peptides, in extra 
hypothalamic brain areas has led to speculation as to the role 
of peptides in neurosecretion and their possible function as 
neurotransmitters or neuromodulators within the central nervous 
system (Gui I lemin, 1978). 
A number of criteria however, must be fulfilled before a substance 
can be defined as a neurotransmitter (Frederickson, 1977), the 
first of which is that it must be present throughout the central 
nervous system usually with a wide and uneven distribution. 
CCK immunoreactivity has been found in most regions of the brain 
of several vertebrate species and has been shown to be attributable 
largely to the COOH-terminal octapeptide although CCK
33 
is also 
present in the brain (Robberecht, Deschodt-Lanckman and Vanderhaeghen, 
1978 ; Muller, Straus and Yalow, 1977). In contrast heptadeca-
peptide gastrin was found only in pituitary stalk and anterior and 
posterior pituitary (Rehfeld, 1978 a, b), whi 1st CCK was absent in 
these areas. 
Tissue extraction of CCK with boiling water was compared with 
0.25 M acetic acid extraction since Dockray (1977a) ; Muller, Straus 
and Yalow (1977) and Rehfeld (1978 a, b) have shown that the 
amounts of structurally related CCK components that can be extracted 
from pigs depends upon the pH of the extraction. Dockray (1980) 
however, has shown subsequent to the completion of th is work that 
the large molecular forms of CCK were obtained in similar yields in 
acid and neutral extracts rn the rat. Thus the optimum extraction 
conditions for the larger molecular forms of CCK in the rat may 
differ from that m pigs. 
The first aim of the study was to investigate the regional 
distribution of CCK in the CNS of the rat. 
MATERIALS AND METHODS 
The tissue dissection of the rat brain along with the extraction 
procedure for tissue CCK has been described in detail in Chapter 
Two. 
Using these techniques the tissue content of CCK 8 from cortex, 
hypothalamus, thalamus, striatum, cerebellum, brain stem and spinal 
cord was measured by radio immunoassay (chapter two), usmg the 
G-2 antiserum. 
Known amounts of CCK
8 
were added to the tissue samples prior 
to extraction, to assess the efficiency of the extraction procedures. 
The lyophil ised extracts were reconstituted in assay buffer, serially 
diluted and assayed for CCK
8 
immunoreactivity. The elution 
volumes of boiling water and acetic acid extracted CCK immune-
reactivity was compared on Sephadex G-50 (sf) chromatography. 
Synthetic CCK 8 and synthetic CCK 33 were also subjected to gel 
filtration chromatography for identification purposes. 
RESULTS 
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A The recovery of CCK 8 added to the brain areas prior to extraction 
m boiling water and acetic acid were 72°/o - 99°/o. 
had no effect on tracer or antibody integrity. 
Tissue extracts 
B CCK/gastrin-1 ike immunoreactivity was extractable in the highest con-
centrations from the cortex, but was also present m lower amounts 
in the hypothalamus, thalamus, striatum, brain stem and spinal cord, 
Lowest concentrations were found in the cerebellum (Table 3.1). 
Results were expressed as nanogram equivalent CCK
8 
per milligram 
of protein. 
C In the hybrid assay system, using 1251-G-17-l as tracer and G-2 
antiserum to G-17-1 and CCK 8, serial dilutions of the extracted 
material caused displacement of tracer parallel to CCK 8 standards 
but not to the SH G-17-1 standards (Fig 3. 1) • 
D The immunoreactive gastrin-1 ike material extracted by boiling water 
from al I areas tested eluted as a single peak in the identical 
region to the synthetic CCK 8 on gel chromatography and no 
material coeluted with G-17 or CCK 33 (Fig 3.2). Acetic 
acid extracts did not differ. 
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Table 3. l 
Regional Distribution of CCK 8 lmmunoreactivity in Rat Central 
Nervous System 
CCK 8 Concentrations 
pmoles/g nmoles/g Protein 
Wet Weight 
Cortex 290 + 13.5 5.82 + 0.27 - -
Corpus Striatum 189 + 7.4 2.62 + 0.10 - -
Thalamus 105 + 3.5 1.30 + 0.04 - -
Hypothalamus 161 + 11. 0 2.04 + 0. 14 -
Cerebellum 9 + 3.8 o. 13 + 0.05 - -
Brain Stem 27 + 2.2 0.42 + 0.03 - -
Spinal Cord 32 + 3.5 0.46 + 0.05 - -
Figures denote mean + SEM (n = 6) 
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fractions from various areas of rat CNS. 
Standard 
CCK 8 
SHG-17-1 
cortex 
hypothalamus 
thalamus 
straitum 
spinal cord 
brain stem 
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D,. - - D,. 
cc 
h 
t 
cs 
SC 
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- 0.82 
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0.77 
0.77 
- 0.79 
0.74 
All brain area extracts diluted in parallel with CCK 8 standards 
(p > 0.05) but not with SHG-17-1 (p < 0.01) 
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Fig 3.2 
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eluted between Vo and Bl 2. 
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DISCUSSION 
The immunoreactive material extracted from the different regions 
of the rat brain was found to be CCK8-I ike. The G-2 anti-
serum used in th is study was more specific for unsul phated 
gastrins than for CCK 8 but crossreacted 7o/o with CCK 8 and 
showed no crossreactivity with a wide range of hormones, pep-
tides and neurotransmitters 
reactivity was found to 
the brain extracts caused 
to CCK 8 standards and 
(Chapter 
correspond 
parallel 
coeluted 
Two). None of the immuno-
to gastrin-1 ike material, al I 
displacement of tracer parallel 
on Sephadex G-50 (sf) chroma-
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tography with synthetic CCK 8 . Th is is in agreement with Dockray 
(1980) who has shown that two CCK8-I ike peptides are the principal 
immunoreactive forms of CCK in rat cerebral cortex, accounting for 
over 90o/o of the total CCK-like activity. 
Dockray (1980) showed that only minimal amounts of CCK immuno-
reactivity corresponded to CCK 33 in rat brain. No large 
molecular weight material was detected in any of the brain 
areas extracted here though if it was present in only very low 
concentrations it is unlikely that the antiserum used, having a 
poor crossreactivity with CCK 33, would detect such low levels. 
Thus the findings of Muller, Straus and Yalow (1977) who found 
CCK
33 
to be prominant in pig brain and Rehfeld (1978 a,b) who 
found CCK
33 
accounted for 2 5o/o of the total immunoreactivity 
in human and pig brain can be explained by species differences 
in the tissue distribution of CCK 33 (Dockray, 1980). 
We were however, unable to differentiate between CCK 8 and the 
COOH-terminal hexapeptide (CCK 6) and tetrapeptide (CCK4) which 
might be present in rat brain (Deschodt-Lanckman, Robberecht, 
Vanderhaeghen et. al. , 1978) and shown to be present in hog 
brain (Rehfeld, 1978b ; Rehfeld and Goltermann, 1979). Dockray 
(1980) has been unable to find any forms smaller than CCK 8 in 
the rat brain but this may have been overlooked due to the 
immunochemical potencies of the different molecular forms. 
possibility still exists that CCK4 may exist in rat brain. 
Thus the 
The concentrations of immunoreactive CCK
8 
material described here 
are similar to those reported by Schneider, Monahan and Hirsch 
(1979) 
humans 
highest 
In 
and 
rats, Vanderhaeghen, 
Muller, Straus and 
Signeau and Gepts (1975) 
Yalow (1977) rn pigs. 
concentration of CCK
8
-like material is found in 
wide and uneven distribution 
This differs from that of 
The 
cortex but 
throughout 
other 
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it is also present with a 
the rest of the rat brain. 
brain peptides in that the cortical amounts of CCK rn vertebrates 
exceeds the amounts of other brain peptides 
10- to 100-fold (Rehfeld, 1978b). Thus it 
that alterations rn the levels of brain CCK 
effects on cerebral function. 
reported so far by 
is reasonable to expect 
might have profound 
CHAPTER F OUR 
SUBCELLULAR DISTRIBUTION OF CHOLECYSTOK ININ OCTAPEPTIDE 
IN BRAIN REGIONS 
INTRODUCTION 
Using appropriate homogenisation procedures, the nerve endings of 
neurones can be sheared from their axon and reseal to form 
intact nerve-endings (Synaptosomes) in which all the main structural 
features of the nerve-ending are preserved (Whittaker, Michaelson 
and Kirkland, 1964). 
The synaptosome thus shows a wide range of metabolic activities 
characteristic of the nerve endings of neurones. These include 
synthesis of lactate and amino acids, generation of ATP and 
phosphocreati nine, accumulation of potassium ions and extrusion of 
sodium ions against a concentration gradient and high linear respi-
ration (Ling and Abdel-Latif, 1968 ; Bradford, 1969 ; Bradford and 
Thomas, 1969). 
A wide variety of hypothalamic hormones and neuropeptides have 
been shown to be present in nerve terminals of the CNS using 
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immunoh istochemical techniques, radio immunoassay and bioassay. These 
include TRH and LHRH (Borneo, Ben-Jonathon, Colston et. al. , 
1975), VIP (G iachetti, Rosenberg and Said, 1976), vasopressin and 
CRF (Mulder, Geuze and de Wied, 1970), SRIF (Epelbaum, Brazeau, 
Tsang et. al. , 1977), enkephal ins (Frederickson, 1977), prolactin 
(Fuxe, Hokfelt, Eneroth et. al. , 1977), substance P (Duffy, Mulhall 
and Powell, 1975) and oC -MSH (Borneo, Oliver and Porter, 1977). 
Straus, Mui ler, Choi et. al. ( 1977) showed by immunoh istochemistry 
that CCK 8 was present in cell bodies of the cortical grey matter 
of rabbits and Pinget, Straus and Yalow (1978) demonstrated CCK-
like immunoreactivity in isolated nerve terminals (synaptosomes) prepared 
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from rat cerebral cortex. The recovery In th is pellet of 40o/o 
of the initial cerebral cortical content of CCK 8 is 
comparable 
to that of VIP (Giachetti, Said, Reynolds et. al. I 1977 ; 
Besson, Rotszteun, Laburthe et. al. I 1979) and SRIF (Epelbaum, 
Brazeau, Tsang et. al. , 1977). 
Depolarising stimuli, high extracellular or electrical stimulation, 
have been shown to stimulate the release of transmitter substances 
1n a calcium - dependent manner. VIP (Giachetti, Said, Reynolds 
et. al. I 1977), substance p (Schenker, Mroz and Leeman, 1976), 
LHRH and TRH (Warberg, Eskay, Borneo et. al. I 1977) have been 
shown to be released from synaptosomes by K+ In the presence of 
+t 
Ca • 
Pinget, Straus and Yalow (1979) showed release of immunoreactive 
CCK from rat 
containing K + 
cortical synaptosomes increased by 200o/o in solutions 
+t 
and Ca • Using Ouso adsorption Straus, Malesci, 
Pi nget et. al • ( 1979) showed that CCK 33 was not re leased under 
non-stimulatory conditions but under stimulatory conditions both CCK 33 
and COOH-terminal fragments were released. 
This&t. data together with other evidence that CCK has an effect on 
satiety suggests that CCK may have an important regulatory function 
at synaptic level in at least the long term regulation of appetite 
(Straus and Yalow, 1979b). 
In this chapter, localisation of CCK 8 immunoreactivity to the
 synap-
tosome fraction of rat brain, in vitro incubation experiments 
the Ca+t d d epen ent release of by depolarising stimuli 
characterisation of the released material will be described. 
showing 
and 
Immune-
reactive CCK 8 was measured by radioimmunoassay using the G
-2 
antiserum. 
/v\ATERIALS AND METHODS 
Dissection of the rat brain into cortex, hypothalamus, striatum and thalamus 
and the preparation of purified intact syanptosomes from these areas has 
been described in Chapter Two. 
70 
A All fractions from the gradient were measured for protein 
estimation after solubil isation in o. 5o/o w/v sodium deoxycholate 
according to the method of Lowry, Rosebrough, Farr et. al. (1951) 
(Chapter Two). Occluded lactate deh ydrogenase (L-Lactate NAD 
oxide reductase) EC 1.1.1.27, an enzyme found in high concen-
trations in the synaptosome fraction of brain homogenates, was 
measured in al I fractions before and after disruption of the membrane 
with Triton X-100. This is generally used as a marker for intact 
synaptosomes (Marchbanks, 1967) (Chapter Two). 
All samples were extracted for iCCK 8 as described in Chapter Two. 
The lyophilised samples were reconstituted in assay buffer immediately 
prior to the measurement of CCK 8 by radioimmunoassay (Chapter Two). 
Proteins, occluded LDH and iCCK 8 from the myelin, mitochondrial 
and synaptosome layers were expressed as a percentage of total 
gradient concentration. 
Samples from the myel in, mitochondria and synaptosome layers were 
fixed in glutaraldehyde and electron microscopy performed on them 
(Chapter Two). 
B To determine the localisation of CCK to synaptosomes, the 
hormone concentration in fractions from continuous 5ucrose density gradients 
was compared with the incorporation of label led neurotransmitters during 
a pre incubation prior to gradient centrifugation. The crude homo-
genates from hypothalamus, cortex, striatum and thalamus were obtained 
as described in Chapter Two and allowed to warm slowly to room 
temperature. One ml was then added to 5ml of KRB as described 
in Section C containing, in addition 
either 
glucose 
adenosine triphosphate 
sodium pyruvate 
ascorbic acid 
10 mM 
0.45 mM 
10 mM 
0. 03 o/o w/v 
[14c] physostigmine h(,drochloride 50 mM (Esserine) with Choline 
5 ,-,I (methyl L14c] Choline Chloride, 52 mCi/mmol, Amersham) 
or 
phenelzine sulphate 100 mM (Nardi!) with [3H] Noradrenaline 
25 µI (L - 7 - [3H] Noradrenaline, 5,8 Ci/mmol, Amersham) 
pregassed with 95o/o o2, 5o/o CO2 • The mixture was incubated 
in a gently shaking water bath at 30°C for 30 min. As a 
control, synaptosomes 
terminated by rapid 
tracer was removed 
were incubated 
cooling ,n an 
by centrifuging 
at 
ice 
the 
4°C. Uptake was 
bath and unincorporated 
mixture at 10 OOOg for 
resuspended by gentle 
homogenisation (Thomas homogeniser, No 54, Thomas Co, Phila-
delphia, U.S.A.) m 0.32 M sucrose, was then applied to a 
5 min at 4°C. The resu I tant pellet, 
I inear continuous density gradient of O. 32 M - 1 .5 M sucrose 
prepared in 30ml cellulose nitrate centrifuge tubes (Beckman 
Instruments) and centrifuged at 75 OOOg for 90 mm in an SW 
25.1 rotor (spinco). The tubes were punctured and 1 ml fractions 
of the gradient collected (Fig 4.0). 100 ,ul was solubilised in 
500 µI sol uene (Packard Instruments), 5ml of scintil lotion fluid, 
lnstagel (Packard) was added to al I samples and the radioactivity 
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determined 
Counter, 
was snap 
by counting 
appropriately 
frozen and 
in a 
set for 
stored 
Packard Automatic 
[ 3H] and [14c]. Liquid The 
at -7.0°C until assayed 
Scintillation 
remainder 
dilution for 
CCK. The same homogenisation and density gradient centrifugation 
procedure was fol lowed on three occasions for each area, without 
prior incubation with label led neurotransmitters, to ensure that the 
CCK profile was unchanged. 
C To study the release of CCK-like immunoreactivity in vitro 
the synaptosome pellet obtained at the end of the preparation (as 
described in Chapter Two) was resuspended by homogenisation (Thomas 
homogeniser, No 54, Thomas Co., Philadelphia, U.S.A.) in Krebs-
-1 Ringer Bicarbonate medium (KRB), (composition mmol/1 ; NaCl 118.5 
NaHC03 25 ; 
CaCl 2 · 2H 20 
with 95o/o 0 2 • 
KC L 4. 7 5 ; Mg So 4 • 7H 2 0 1 • 1 8 ; K H / 0 4 l • 1 8 ; 
7.4, containing 10 mM D-glucose and 
m final concentrations equivalent to 
hypothalamus, ! striatum and 1/6 of a cortex per ml. 
pre gassed 
thalamus, 
These 
concentrations were strictly adhered to throughout all experiments. 
{\ 0.32M ~ 5ucrose 
~!Q'f,W/V~ 
12 passes 
up & down 
900 r. p. m. 
0. 25 mm 
clearance 
Fig 4. 0 
75,000g 
X 
90 min. 
30ml Gradient 
0.32M -.1.5M Sucrose 
+ -' Incubated with 14c - Choline 
- 3H Noradrenaline 
To determine the localisation of CCK 8 tissue homogenates were 
incubated with [ 14c] choline and [ 3H J noradrenaline and separated 
into subcel lular fractions on a continuous density gradient of 
0.32 M - 1.5 M sucrose. 
collected. 
l ml fractions of the gradient were 
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Incubations were carried out m stoppered glass vials (10ml) 
containing 0.5ml aliquots of synaptosome suspensions, placed 
in a gently shaking water bath at 37°C. The synaptosomes 
were pre incubated for 25 min before the addition of test 
substances and thereafter for a further 30 min in an atmosphere 
of 95o/o 0
2 and 5o/o CO2° To study the release of immuno-
reactive CCK in response to depolarising stimuli and the calcium 
dependence of this release the following test substances were 
added to give final concentrations of 
KCI 60 mM 
Veratrine 75 pM (Sigma) 
KCI 60 mM + Ethyleneglycol - bis - (p-aminoethyl ether) 
(NN'-tetra-acetic acid (EGTA, Sigma) 1 mM 
Veratrine 75 JJM + tetrodotoxin 1 µM (Calbiochem) 
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An equal volume of medium was added to the control incubations. 
After the 
fuged for 
removed, 
30 min period of incubation 
5 min at 2 x l o3 g at room 
boiled, snap frozen and stored 
the suspension was centri-
temperature, the supernatent 
at -20°c f or measurement 
of 
and 
i mmunoreact i ve 
control release 
CCK 
of 
(Chapter 
iCCK 8 
Two). Differences 
were evaluated with 
between 
the use 
test 
of 
Wilcoxon unpaired ranking tests (Mann-Whitney) for non-parametric 
data. 
D In a further set of experiments 0.5ml suspensions of 
rat cortical synaptosomes were incubated for 15, 30 or 45 min 
periods with and without the addition of 60 mM KCI to determine 
the time course of the release of iCCK 8• 
E Oxygen consumption, as measured by the Warburg technique, 
(Bradford, 1969) was used as an estimation of metabolic activity on 
a suspension of cortical synaptosomes (Chapter Two). 
25 mM replaced NaHC03 in the incubation medium which was gassed 
with l OOo/o o2 • To assess membrane integrity of the incubating 
synaptosomes, occluded LDH was measured at 0, 15, 30 and 45 
min periods of incubation from hypothalamic and cortical synaptosomes. 
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F To establish identity of the iCCK 8 the synaptosome pellet 
was extracted as previously described in Chapter Two and serial 
dilutions were compared for parallel ism to the immunoassay dose 
response curve. In addition the elution profile of the extract 
was compared after ge I chromatography, Sephadex G-50 (sf) with 
that of synthetic CCK 8 (Chapter Two). 
RES UL TS 
A. Continuous sucrose density gradient unltracentrifugation of 
homogenised hypothalamus, thalamus, striatum and cortex revealed a 
r,ak- of CCK 8 immunoreactivity, coinciding with the peaks of L' 4c] choline and [ 3H] noradrenaline uptake (Fig 4. 1). The specific CCK 
peak retained the same sedimentation characteristics when studied with-
out prece ding incubation. Another peak of CCK immunoreactivity 
in high concentration occurred 
coinciding with unincorporated 
in the 0. 32 M area of the gradient 
[14c] choline or [ 3H] noradrenaline. 
The addition of sucrose in equivalent concentrations to that in the 
gradient fractions (1.5 M, 1.2 M, 0.8 M, 0.32 M) did not cause 
displacement of the CCK 8 dose response curve. 
B. The purified synaptosomal fraction obtained fol lowing 
differential centrifugation and ultracentrifugation on a discontinuous 
sucrose density gradient contained more than 60o/o of the CCK immune-
reactivity recovered from all four areas. This immunoreactivity 
coincided with the major concentration of occluded LDH activity 
and gradient protein (Fig 4.2). Electron microscopy i.e. exam-
ination of glutaraldehyde fixed samples of all gradient fractions from 
hypothalamus and cortex confirmed the major concentration of intact 
synaptosomes to coincide with CCK immunoreactivity, protein and 
occluded LDH activity (Fig 4.3, 4.4, 4.5). Fig 4.6 shows a 
synaptosome particle packed with secretory granules. 
C. 
significant 
areas of 
shown by 
Both 60 mM KCI 
release of iCCK 8 
the brain studied. 
the inhibition of 
and 75 pM veratrine stimulated a 
from the synaptosomes from all four 
This release was calcium -dependent as 
release by the calcium chelating agent 
EGTA. Furthermore, veratrine-stimulated release, which occurs 
by the opening of sodium channels was inhibited by its 
specific antagonist tetrodotoxin (Table 4.1). Test substances 
did not crossreact with the G-2 antiserum. 
D. A time course study showed that both basal and stim-
ulated release of iCCK 8 increased over the full 30 mm period, 
whereafter the rate of release decreased (Fig 4.7). 
E. The synaptosomes prepared from hypothalamus and cortex 
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were found to be intact over the 45 mm of incubation. Results 
(Table 4.2) demonstrate occluded LDH expressed as a percentage 
of the total LDH activity, remains constant throughout the 45 min 
period whereas the supernatents from each of the time periods 
(i.e. for measurement of released iCCK 8) contained no LDH activity. 
Suspensions of cortical synaptosomes remained metabolically active over 
a 55 min period of study as shown by linear oxygen consumption 
over that time. Mean oxygen consumption was 66. 0 + 7. l µmol 
0 2 /100mg synaptosome protein hour (n = 6) (Fig 4.8). 
F. Extracts from cortical synaptosomes diluted out in para I lel 
to CCK 8 but not to G-17-1 and coeluted with synthetic CCK 8 
on gel chromatography (Fig 4.9). 
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Fig 4.3 
Myelin fraction X 12 000 
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Fig 4. 4 
Mitochondrial fraction x 5 000 
m mitochondria 
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Fig 4.5 
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Fig 4.6 
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Triton X-100, to disrupt the 
for 10 min at 1.7 x 10
3g at 
synaptic 
4°C. 
membranes and centrifuged 
500 111 of supernatent was 
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transferred to 25ml scintillation vial (Packard), 5ml of scintillation 
fluid, Dimilume (Packard) was added to all samples and the radio-
activity determined by I iquid scintillation counting with a Packard 
Tricarb Z650 appropriately set for [
3H] and [ 14c J . 
C 2) Potassium-stimulated release in relation to time of basal 
perifusion. 
To show that l 00 mM 
equal I y throughout the 
K + -stimulated release occurred 
perifusion, K+ -stimulated release 
at all 
was 
times 
compared 
in three simultaneous paral lei channels at times 0, 35 and 70 
min fol lowing the 
of 30 min. In 
substance stimulus 
time ~ 65 min 
equilibration 
addition, in 
100 mM K+ 
period of 45 min and basal period 
al I experiments after an initial test 
was used in a second stimulus at 
(i.e. + 130 min after the perifusion was started) 
to check on the functional viability of that particular column of 
synaptosomes. If K+ given at this time did not cause CCK 8 
release from a column which had not previously released CCK 8 at 
first stimulation, the preparation was considered non-functional. 
C 3) [ 14c] chol ·1ne k f b upta e a ter exposure to a test su stance. 
In a number of experiments [14c] -c and eserine 100 mM were per if used 
following the 20 min period of stimulation to assess the viability of 
the synaptosomes immediately after stimulation. 
D. The ability of synaptosomes to release CCK 8 in response to 
a depolarising stimulus in a calcium-dependent manner was tested by 
parallel perifusion with l 00 mM KCI in 
1 mM EGTA. Veratrine (75 pM) was 
depolarising agent in another experiment 
KRBGG 
employed 
and the 
with and without 
as an alternative 
specificity of this 
response investigated by the addition of 1 µM tetrodotoxin along with 
veratrine in a para I lei channel. In these experiments a smaller 
final volume of 4ml was used and distributed between two perifusion 
columns. 
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E. Neurotransmitters used to study the modulation of CCK 
release in vitro were 
Dopamine 
Noradrenaline - HCI 
Serotonin 
Acetyl Choline perchlorate 
(Sigma) 
(Sigma) 
(Sigma) 
(BDH) 
All were used at the concentrations of l0-4M, l0-6M and 10-BM 
dissolved in K RB containing 0. 01 o/o ascorbic acid. 
F. The synaptosome suspension was extracted before and after 
perifusing with l 00 mM KC I to determine how much of the total CCK 
immunoreactivity was released 1n response to a test substance. 
G. Enzymic degradation of released iCCK 8 was assessed by 
perifus ing l Ong of synthetic CCK 8 through the synaptosomes. A 
pooled basal release was obtained and subtracted from the amount 
recovered after perifusion with synthetic CCK
8
• 
H. To establish identity of the released material synthetic CCK
8 
and CCK 8 immunoreactivity extracted from cortex by boiling in neutral 
distil led water were fractionated on HPLC using a reverse phase system 
(Spectraphysics RP 8 10) 25cm x 0.46cm. Solvent A was lOo/o methanol, 
0. 01 M ammonium acetate pH 4. l, and solvent B was 90o/o methanol, 
0. 01 M ammonium acetate pH 4. l. A I inear gradient of 30o/o B to 
90o/o B was run over 15 min at a flow rate of l • 6ml/min. In 
addition boiling water extracts of cortex and the material released 
after KCI depolarisation was applied to a Sephadex G-50 (sf) column 
(Chapter Two). 
I • Stimulated release was calculated as the integrated response 
above basal by the formula described by Richardson, Walsh, Hicks et. 
al. (1976) and expressed n mol, -1 Differences between as m,n, ml . 
basal and stimulated responses were compared by Wilcoxon signed rank 
test for paired samples. 
RES UL TS 
A. During 
showed a high 
a steady basal 
perifusion with KRBGG 
rate of release of CCK 8 
+ 
state of (- 15pg/ml) by 
the 
of 
state remained constant over 30 - 140 min 
synaptosomes initially 
+ (- 5ng/ml) falling to 
Th is basal 
(Fig 5.3 inset). An 
equilibration time of 45 min was therefore chosen for al I further 
experiments prior to the collection of any samples. 
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B. The iCCK content in the synaptosome pellets, from each 
column, after extraction was 
column 
2 
3 
pg/mg protein 
562.9 
577 
652 
Thus it appears that the syanptosomes were equally distributed between 
the columns. This was also confirmed by the protein estimation of 
the column contents over a number of experiments. 
C. C 1) 
noradrena Ii ne and 
Incorporation of 
The synaptosomes were found 
[ 14c J choline over the 135 
the neurotransmitters over the 
to incorporate [ 3H] 
min of incubation. 
0 - 45 min period was 
lower than at the 45 - 90 or 90 - 135 min periods which were 
similar. This process could be inhibited by 
inhibitor ouabain (10-4 M) or by inactivating 
per if using at 4°C. Diminution of uptake of 
[ 14c J choline occurred regardless of whether 
or 90 - 135 min was chosen as the control 
the addi t ion of the A TPase 
the metabolic processes by 
[ 3H] noradrenaline and 
0 - 45 min , 45 - 90 min 
time period (Fig 5.4). 
C 2) Peaks of CCK immunoreactivity released m response 
to the depolarising stimuli 100 mM KCI occurred over the 135 min of 
incubation, a peak being associated with each time period of O -
35, 35 - 70, 70 - 105 (Fig 5.5). A 
in response to the depolarising stimuli 
second peak 
100 mM KCI 
of 
. 
after 
released 
45 mm 
iCCK 
at 
basal conditions could be demonstrated after previous exposure to a 
99 
test substance. This second peak was lower than the first peak if 
the test substance had caused release of CCK. If the test substance 
had failed to cause any release of CCK it could be shown that 
the addition of 100 mM KCI caused a greater release of CCK than 
,n the channel that had previously been stimulated (Fig 5.7). 
C 3) When [ 14c J choline and eserine were added 
immediately after stimulation, a second peak of released iCCK could 
be demonstrated which was greater 
to the test stimulus (Fig 5.9). 
similar to the 45 - 90 and 90 
than 
Uptake 
the 
of 
initial peak in 
[ 14c J choline 
response 
was 
135 min periods rn experiment C l). 
D. The depolarising stimuli, high extracellular K+ and veratrine 
caused a significant increase in the release of CCK. 
induced 
chelating 
release 
agent, 
inhibited by the addition 
h d · the Ca++ t us emonstrat ing 
of the Ca++ 
dependence of 
this release (Fig 
could be 
EGTA, 
5. 3). The veratrine induced release could be 
inhibited by 
(Fig 5. 6). 
was greater 
the 
The 
than 
addition of its specific antagonist, tetrodotoxin 
integrated release of CCK 8 in these experiments 
those reported below because of the higher concen-
tration of tissue used per column. 
reactivity with the G-2 antiserum. 
Test substances had no cross-
E. 
drenal ine 
Per if us ion 
at l 0-4M I 
and nora-neurotransmitters, serotonin 
and l 0-BM concentrations had no effect 
Dopamine at l0-4M on the release of CCK (Fig 
concentration had no effect 
in the release of CCK (Fig 
5.7) 
while 
5. 8). 
5. l). 
caused 
Dopamine 
a 
at 
significant increase 
10-BM concentration 
caused re lease rn four out of five cases but th is did not reach 
statistical 
at 10-4M 
significance (Table 5. l). 
and l 0-8M concentrations 
Perifusion with 
had no effect 
acetyl 
while 
concentration significantly increased the release of CCK (Fig 5. 9) 
(Table 5.1). There was no crossreactivity with the G-2 antiserum· 
with any of the test substances used. 
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F. 18.9o/a : 3.77% (n = 3) of the total amount of iCCK 
present in the synaptosomes was released in response to the depola-
rising stimulus of l 00 mM K Cl. 
G. Recovery of 
synaptosomes was 90. l 
synthetic CCK 8 
+ 7.8o/a. 
per if used through the incubating 
H. Boiling water extracts of cortex yielded radio immunoassay 
displacement curves paral lei to those of synthetic CCK 8 standards 
(Fig 3.1) and coeluted with synthetic CCK 8 with both the HPLC 
(Fig 5.10) and Sephadex G-50 (sf) chromatography (Fig 5.11). 
In addition the synaptosome release material coeluted with both the 
cortical extracts and the synthetic standards. Th is does not however, 
exclude the possibility of other CCK-like peptides being released 
but rather demonstrates the relative specificity of this antiserum for 
CCK 8 • 
CCK 8 
1700 
~ 11001 
0 
E 
8 
C:0900 
::x:: 
0 
0 
700 
500 
-20 
release from 
to 100 mM KCI and 
Fig 5.3 
,I~ 
3 23 43 
TIME 
-10 0 20 
TIME [mins] 
parallel synaptosome/Bio-gel 
100 mM KCI + EGTA. 
40 
columns in 
The inset shows release of CCK 8 
immediately following the 
ment of perifus ion. Stable release occurs after 30 min. 
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response 
commence-
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Fig 5.4 
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Fig 5.5 
6 •K+ •K+ oK+ 
• • • 
450 
250 
TIME [mins] 
Release of CCK
8 from synaptosomes in response to 100 mM KCI at 
varying times over 135 min after the commencement of perifusion. 
The figure does not indicate the 45 min equilibration and 30 min 
basal periods preceeding the first stimulus. 
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CCK 8 release from parallel synaptosome/Bio-gel columns is response 
to 75 pM veratrine and 75 µM veratrine + 1 µM tetrodotoxin. 
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Fig 5. 7 
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Basal release (f mol/min/column) did not differ significantly between 
groups of experiments. Results are expressed + as mean - S EM where 
the number of experiments are indicated. 
* p < 0.05 significant response above basal 
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Perifusion with 100 mM KCI in the control column and 
(l0-6M) in a parol lel column caused significant release 
from the synaptosomes. 100 mM KCI stimulated release 
columns 58 min ofter initial stimulation. 
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dopamine 
of CCK 8 
in both 
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Fig 5.9 
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-6 (10 M) in three parallel columns caused significant release of CCK 8 
from the synaptosomes. In addition, eserine, l 00 mM and 
[ 14c] choline added to al I columns after stimulation caused 
a second peak of CCK 8 release. 
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Boiling water extracts of cortex coelute as a single peak with 
CCK 8 standards on HPL
C. 
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Fig 5. 11 
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Gel chromatography of boiling water extra:: ts of cortex ( --- ) 
and the cortical synaptosome release material (a---11) on Sephadex 
G-50 (sf). The column was equilibrated with synthetic human 
heptadecapeptide gastrin (SHG-17-1), cyanocobalamin (B12), cholecys-
tokinin octapeptide (CCK 8), pentagastrin (PG) and potassium iodide 
(KI). 
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DISCUSSION 
The use of a perifusion system to study re lease of peptides from 
isolated synaptosomes has several advantages over the conventional 
incubation method. These are the low basal release of peptide, 
the low rate of peptide degradation and the ability to elicit 
multiple stimuli from the same preparation. 
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In previously described continuous synaptosome superfusion techniques, 
the synaptosome fraction was layered on a G-15 Sephadex bed and 
samples collected for 60 (Bosse and Kuchinsky, 1978) and 90 
(Mulder, Van Den Berg and Stoof, 1975) min after commencement 
of the perifusion. 
The system described here differs from these in that the synaptosomes 
are distributed throughout the Bio-gel mesh which acts as a bed 
matrix and appears to provide a stable protective support for the 
synaptosomes, which remain functionally viable for at least 2! 
hours. 
Using this technique we have been able to demonstrate that there 
is a high release of CCK 8 during the equilibration per
iod which 
probably reflects the removal of peptides released from synaptosomes 
during their 
first 45 min 
preparation and 
of perifusion, 
from non intact synaptosomes. During 
[ 14c] choline and [ 3H J noradrenaline 
uptake was lower than in subsequent periods. The 45 min equili-
bration period thus allows the synaptosomes to return to an optimal 
functional level and permits the removal of non-occluded peptide. 
Using a static incubation technique early release during the equil i-
bration period is included in the basal release and thus the 
the 
relative increase of the stimulation may be poor. Another advantage 
of the present system is that we have been able to demonstrate 
that the synaptosomes respond fully for at least 160 min after the 
beginning of the per if us ion and moreover the same pre pa rat ion may 
be stimulated a second and possibly even a third time. Lastly, 
the per if us ion technique potentially has yet another advantage in 
that exposure to released degradative enzymes is obviated by the 
continuous flow and rapid boiling of the perifusate. We have 
demonstrated 90o/o recovery of CCK 8 in the absence of protease 
inhibitors which compares to 20o/o reported by Dockray, Dodd, 
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Edwardson et. al. (1980) using the static system. A disadvantage 
of th is system however, is the large number of samples generated 
for each experiment. 
The exposure of synaptosomes to 100 mM KCI or 75 fJM veratrine 
stimulated 
increasing 
the 
the 
release of 
ext race II ul or 
CCK8 • As 
concentration 
discussed in Chapter 
reduces the 
Four, 
potential 
difference across the membrane whereas veratrine ts thought to open 
+ Na -channels, both generating an action potential (Li and White, 
1977). 
specific 
release 
by the 
This veratrine- stimulated release can 
· d · The Ca++ antagon 1st, tetro otoxtn. 
is demonstrated by the inhibition of 
Ca++ chelating agent EGTA. 
be blocked by its 
dependence of this 
K+ stimulated release 
To date there have been no reports regarding neurotransmitter control 
of release of CCK 8 from brain. We have shown dopamine and 
noradrenaline stimulated CCK 8 release from isolated incubated hypothalami 
(Chapter Six). The finding that CCK 8 release occurred in response 
to dopamine and acetylchol ine at 10-6M but not in response to the 
-4 higher concentrations implies that high (10 M) dopamine and acetyl-
chol ine are able to reverse the effect at 10-6M. Whether this 
ts due to actions on different types of receptors (Kebabian and 
Caine, 1979) with different effects or due to opposite effects of 
neurotransmitters on different popu lotions of CCK synaptosomes from 
different areas, cannot be determined in this study. A similar 
Cotte made by Bennett, Edwardson, Marcano De finding 
(1979) 
was 
using hypothalamic synaptosomes where they re ported that 
-4 dopamine stimulated somatostatin release, whereas 10 M dopamine 
inhibited release. Denef, Manet and Dewa Is ( 1980) have re ported 
both stimulatory and inhibitory effects of hign and low dose dopa-
mine on prolactin release from cultured pituitary cells. Hokfelt, 
Rehfeld, Skirboll et. al. (1980) have shown the co-existence of 
CCK-1 ike peptides in a subpopulation of dopaminergic neurones tn 
rat and man. 
in fore bra in. 
These neurones project to mesolimbic areas 
CCK fragments have been shown to inhibit 
dopamine release in the nucleus accumbens and tuberculum 
olfactorium region. Hokfelt, Rehfeld, Skirbol I et. al. (1980) 
suggested that the peptide released together with the main 
neurotransmitter dopamine, may be part of an inhibitory system 
modulating dopamine release via an action on autoreceptors. 
The data presented here which demonstrates that CCK
8 is 
re-
leased by dopamine IS consistent with such an autoreceptor 
hypothesis. 
In conclusion we have devised a new technique for perifusing 
brain synaptosomes dispersed within a Bio-gel P2 column which 
obviates many of the difficulties experienced with static incubation 
systems. Rat cortical synaptosomes release CCK
8 rn response to 
depolarising stimuli of l 00 mM KCI and 75 pM veratrine and the 
release is calcium-dependent. Moreover the demonstration that 
neurotransmitters affect CCK
8 release rn physiological concentrations 
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provides further evidence for CCK 8 being a modulator 
function. 
of neuronal 
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CHAPTER S IX 
CHOLECYSTOK ININ OCTAPEPTIDE RELEASE FROM INCUBATED 
RAT HYPOTHALAMI 
INTRODUCTION 
CCK was found to be widely distributed throughout rat brain (Chapter 
Three). The highest concentrations of CCK have been found 1n the 
cerebral cortex but in addition high concentrations are present in the 
hypothalamus. lmmunocytochemical studies have shown the presence of 
CCK-1 ike immunoreactivity in the dorsomedial nucleus of the hypo-
thalamus (Innes, Correa, Uhl et. al. , 1979 ; Larsson and Rehfeld, 
1979) whilst the presence of CCK 8 in rat hypothalamic synaptosomes 
and the release of CCK 8 from the synaptosomes by depolarising 
stimuli has been demonstrated in Chapter Four. Morley, Mel med, 
Briggs et. al. (1979) have demonstrated that CCK
8 
releases growth 
hormone from isolated rat pituitaries whilst Domschke, Lux and 
Domschke (1980) demonstrated that the structurally related peptide, 
pentagastrin, stimulates growth hormone secretion tn man. These 
studies suggest a possible hypophysiotrophic role for this peptide. 
In view of this possible role of CCK as regulator of GH we 
have examined the regulation of CCK release from hypothalami. 
The hypothalamic block was dissected to include parts of the para-
ventricular, dorsomedial, ventromedial, suprochiasmatic and arcuate 
eminence (Hirooko, Hollander, Suzuki et. as well as the median 
1978) all of which have 
contain CCK (Table 1.3). 
been shown by immunoh istochemistry to 
MATERIALS AND METHODS 
nuclei 
al. ' 
Hypothalamic blocks, l mm deep and bounded by the optic chiasm, 
lateral grooves and mamillary bodies, were dissected from male Long-
Evans rots within - 2 min and placed in a glass incubating dish 
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(100ml) containing incubation medium. 
The incubation medium consisted of 
NaCl 
NaHC03 
KCI 
CaCl 2 
NaH 2PO 4 
MgS04 ·7H 20 
D-glucose 
Gelatine 
126 
22 
6 
1.45 
1 
0.88 
11 
o. l 
mM 
mM 
mM 
mM 
mM 
mM 
mM 
% w/v (Hopkins and Williams) 
The hypothalami, 
at 37°C, in an 
at all times, were incubated in a shaking water 
atmosphere of 95% 0 2, 5% CO2 . Following a 
bath 
60 min pre incubation period the hypothalami were individually placed 
in stoppered glass vials (10ml) containing 0.5ml of incubation medium 
or 0.5ml of test medium. After 30 min of incubation the medium 
was decanted, boiled, f d t d t -20°C unt·,1 snap rozen an s ore a assayed 
for ·CCK 8 immunoreactivity. 
A. Viability of the incubating hypothalami was assessed by the 
fol lowing studies 
A l) o2 Consumption 
Their ability to consume oxygen using the Warburg constant volume 
manometer (Chapter Two). The incubation medium was gassed with 
l 00% oxygen, bicarbonate being replaced by phosphate (Na2HPO 4, 
22 mM). 
A 2) Protein Synthesis 
Their capocity to synthesise proteins as assessed by the incorporation 
of a label led [ 3H] amino acid mixture into the perchloric acid 
precipitable protein fraction and the inhibition of this incorporation 
by specific inhibitors of protein synthesis. Individual hypothalami 
were incubated in a shaking water bath at 37°C in 0. 5ml of 
medium (as for incubation experiments) containing 20 pCi [ 3H] amino 
acid mixture (code TRK 440 ; Batch 26 ; radioactive concentration 
of mixture 1 mCi/ml) (Radiochemical Centre, Amersham, England). 
In some experiments, puromycin (Sigma) 1 000 µglml and cyclo-
heximide (BDH) 500 µglml were added to the incubation medium. 
At time 2, 30, 60 and 90 min hypothalami were removed and 
placed in [ 3H J amino acid free medium to wash off any excess 
label from the surface of the block and then homogenised in 
2ml ice-cold distil led water. 200 µI of cold 1 M perchloric 
the homogenate 
3 
to preci pi tote protein 
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acid 
and 
was added to 
centrifuged for 
200 µI of 
10 min at 1 .7 X 10 g at 4°C. The · · prec1p1tate 
was washed three times by resuspending in 200 µI of cold 0. 5 M 
perchloric acid and recentrifuging. The final pellet was resuspen-
ded m 200 JJI of distilled water, the tube washed out with a 
further 200 ,-,I of water and transferred to a 25 ml glass scintillating 
vial (Packard). The sample was solubil ised by the addition of 
800 ,-ii of soluene 350 (Packard). 5ml of scintillation fluid, 
Dimilume (Packard) was added to al I samples and the radioactivity 
determined by I iquid scintillation counting with a Packard Tricarb 
Z650 appropriately set for [ 3H J . 
B. In pre I iminary experiments the pre incubation time of 60 
was determined by incubation in medium for 30, 45, 60 and 90 
min while the post stimulation time of 30 min was determined by 
incubation with and without 60 mM KCI for 15, 30 and 45 min. 
c. 1 Ong synthetic CCK 8 was added to the medium of 8 
incubating hypothalami. After 30 min of incubation the recovery 
min 
of the added CCK 8 was compared to the endogenous CCK 8 released 
from a parallel set of hypothalami without the addition of synthetic 
CCK 8 • 
D. To show identity of the released material to CCK
8
, serial 
dilutions were prepared in assay buffer and measured for CCK
8 
immunoreactivity. In addition the elution profile of the material 
was compared after gel chromatography, Sephadex G-50 (sf) with that 
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of synthetic CCK 8 (Chapter Two). 
E. To study the release of immunoreactive CCK 8 in response 
to depolarising stimuli and the calcium dependence of this release. 
The following substances were individually made up in the previously 
described 
Medium 
incubation 
KCI 
Veratrine 
medium to 
60 mM 
75 pM 
give final concentrations of 
(Sigma) 
KCI 60 mM + Ethyleneglycol - bis - (p - aminoethyl ether) 
N N 
1 
- tetra-acetic acid (EGTA, Sigma) l mM 
Veratrine 75 µM + tetrodotoxin l µM (Calbiochem) 
Calcium ionophore A23187 0.1 µM (courtesy of Lilly Labo-
ratories). 
containing no Ca++ was prepared by substituting choline 
chloride for CaCl 2 . 
F. Neurotransmitters used to study the modulation of CCK 8 
release in vitro were 
L Dopamine l0-4M 
' 
10-6M, 10-BM and 10-l OM 
2. Noradrenaline 10-4M I 10-6M 
' 
10-BM and 10-lOM 
3. Serotonin 10-6M and 10-BM 
4. Acetyl Choline 10-6M and 10-BM 
0. 01 o/o ascorbic acid was added to each neurotransmitter to prevent 
oxidation. 
G. The release of CCK 8 m response to dopamine 10-
6M, 
which was found to release CCK
8 
was studied following preincubation 
of the hypothalamus with the fol lowing preparation for l O min. 
1. 
2 . 
3. 
rat growth 
somatostatin 
phentolamine 
hormone 
(SRIF) 
(CIBA) 
(rGH) NIAMDD -
Laboratories 
and 10-B 
rat EH-RP- I 
concentrations 
Dopamine was then added to give a final concentration of 1 o-6M 
and the incubation continued as previously described. 
CCK
8 
was measured using the CP6 antiserum (Chapter Two). 
H. Significant differences between the release of iCCK 8 in 
response to the test substance and the release observed in normal 
medium (control) were evaluated by the students t test. Due to 
variation in basal release of iCCK 8 between 
experiments, control 
results in each experiment were corrected to a mean absolute 
value while test results within the some experiment were similarly 
corrected using the correction factor derived for that experiment. 
RESULTS 
A 1) Oxygen consumption from the 
the 120 min period studied 
incubated hypothalami was 
I inear over ( r = 0 • 89 I P .::._ 0 • 00 l 
(Fig 6. 1). 
0 2 / g,hr 
Mean 
(mean 
oxygen consumption + was 1 1 4. 1 - 6. 5 µ mo I 
°2: SEM I n = 6). 
A 2) The hypothalami incorporated [ 3H] amino acids into the 
protein precipitable fraction in a linear fashion, over the 90 min 
of incubation (Fig 6.2) (r = 0.92, p < 0.001). 
of puromycin 1 000 ,uglml and 
78. 3 "2: 0. 8o/o inhibition (mean 
cycloheximide 
+ 
[ 3H] amino acid mixture at 90 SEM, n min. 
500 µglml 
= 6) of 
The addition 
resulted m 
incorporation 
B. CCK 8 release was uniform from 60 min 90 min 
pre incubation. A pre incubation time period of 60 min was 
used for all subsequent experiments. The time-course of release 
showed that CCK
8 
release increased up to 30 min. 60 mM KCI 
caused significant increase in release relative to control at this 
118 
of 
time period. 
(Fig 6.3). 
Total release of CCK 8 up to 45 min was diminished 
Degradation or reuptake of released CCK 8 
probably 
occurring after 30 min of incubation. 
C. The recovery of synthetic CCK 8 added to 
the incubating 
-±: SEM, n = 
hypothalami 
8). 
for 30 min was + 87 .5o/o 
the medium of 
8. 1 o/o (mean 
D. The released material caused displacement of 1251-G-l 7-l 
parallel to that of CCK 8 standards (Fig 6.4) and coeluted 
with synthetic CCK 8 on gel chromatography (Fig 6.5) 
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E. Release of CCK 8 
stimuli, 60 mM KCI 
was 
and 
significantly increased by the 
release 
de pol-
arising 75 µM veratrine. The 
response to high was inhibited in the presence of the calcium 
chelating agent EGTA and the release in response to veratrine 
inhibited by its specific antagonist, tetrodotoxin. 
ionophore 
in the 
A23187 significantly 
++ 
absence of Ca (Fig 
stimulated re lease. 
6. 6). 
The calcium 
No release occurred 
F. Dopamine at -6 10 M and l 0-8 M concentrations caused 
a significant release of CCK 8 with the maximal effect caused by 
l0-6M (p < 0.001) (Fig 6.7). Results obtained with noradrenaline were 
inconsistant at all the concentrations used and no conclusions could be 
drawn. There was no significant release of CCK 8 in response to any 
of the other neurotransmitters at the concentrations used (Table 6. 1). 
G. SRIF at all concentrations did not significantly alter the 
dopamine effect. Similarly rGH which has been shown to cause 
SRIF release from the isolated hypothalamus (Sheppard, Kronheim and 
Pimstone, 1978) did not alter l 0-6M dopamine-stimulated CCK 8 release. 
Phentolamine 10-6M and l0-8M which is a specific 0<.. -adrenergic 
blocker significantly inhibited dopamine-stimulated CCK 8 release 
(p < 0.001) (Table 6.2). 
N 
0 
:i... 
10 
80 
20 
Fig 6. 1 
• 
• 
• 
o....._.___-,-----,-----r------1 
30 60 90 
TIME (mins) 
Oxygen consumption (j.Jl 0 2) by hypothalami 
(r = 0.8865, p < 0. 001, results from 5 experiments) 
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Fig 6.2 
25 
15 
5 
2 30 60 90 
TIME (mins) 
Incorporation of [ 3H] amino acids (dpm x 1 o3; 200 f I) by 
incubated hypothalami into the perchloric acid-precipitate. 
+ Histograms represent mean - SEM of 6 experiments at each time 
point (r = 0.9169, p<0.001) 
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Fig 6.3 
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cu 
cu 
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Time course of release of CCK
8 
immunoreactivity from incubated 
hypothalami 
p < 0.01 
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Fig 6.4 
• 
• 
Sample 
1:4 
250 
Dilutions 
1:2 
500 
CCK8 pmol/1 
1000 2500 
vs loge of CCK 8 
standards (r = - 0. 1) with 
of 125 t-G-17-l by serial dilutions of released 
incubated rat hypothalami (r = - l. 2) 
F = 4. 257 (df l . 24) by analysis of covariance. 
p > 0.05 
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Fig 6.5 
G-17 CCK-8 PG 
.... .... .... 
Kl 
.... 
175 200 225 250 
Elution Volume [ml] 
Gel chromatography of released material of incubated rat hypothalami 
on Sephadex G-50 (sf). The column was equilibrated with synthetic 
human heptadecapeptide gastrin (SHG-17-1 ), cyanocobalamin (B 12), 
cholecystokinin octapeptide (CCK 8), pentagastrin (PG) and potassium 
iodide (K I). 
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Fig 6. 6 
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HYPOTHALAMIC INCUBATION 
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+K 
Effect of two depolarising stimuli (60 mM KCI and 75 fJM veratrine) 
on the release of CCK 8 and the 
tetrodotoxin and 1 mM EGTA. In 
inhibition of release by pM 
the absence of Ca++ ions and 
in the presence 
was significantly 
++ 
of the Ca ionophore A23187 re lease of CCK 8 
decreased. Histograms represent mean ": SEM of 
number of experiments indicated. Significant differences between 
test and control release results are shown by ~ (p < 0. 01) 
Fig 6.7 
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0 Dopamine 
Effect of Dopamine (1 o-4M, -8 -10 10 M and 10 M) on 
immunoreoctive CCK 8 release from rot hypothalami. Histograms 
represent mean : SEM of number of experiments indicated. 
Significant release over control release 1s shown by * (p < 0.05) 
** (p < 0.01) * * * (p < o. 001) 
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Concentration 
ACETYL 
CHOLINE 
SEROTONIN 
Effect of Acetyl 
Mean 
SEM 
n 
Mean 
SEM 
n 
Table 6. 1 
Basal 
68.2 
9.6 
16 
74.2 
11.7 
18 
86.9 
12. 1 
13 
119. 4 
21.6 
14 
-6 -8 Choline and Serotonin at 10 M and 10 M 
concentrations on CCK 8 release from isolated hypothalami. 
Values given are p mol CCK 8 released/ Hypothalamus/ 30 min. 
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95.9 
14.4 
16 
93.55 
17.8 
14 
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DISCUSSION 
A prerequisite of physiological studies on CCK release 
thalami is the establishment of systems for the viable 
of the hypothalami over the period of incubation. 
shown by other workers that incubated hypothalami are 
by hypo-
maintenence 
It has been 
capable of 
consuming oxygen over a three hour period (Bridges, Hillhouse and 
129 
Jones, 1976 ; Bigdel i and Snyder, 1978 Hiraoka, Hollander, Suzuki 
et. al. , 1978; Berelowitz, Kronheim, Pimstone et. al., 1978). 
We have verified this with the use of the Warburg constant volume 
manometer and found oxygen consumption to be I inear over a 120 
min period at a rote of 114.1 µmol oxygen/g.hr similar to the 
68. 9 - 120 JJmol oxygen/g, hr reported by Bradbury, Burden, H ii I house 
et. al. (1974). 
We have selected protein synthesis as an additional and probably 
more reliable index of tissue viability 
wide spectrum of biochemical pathways 
of subcel lular structure. Incorporation 
since it IS 
as well as 
of a [3H J 
dependent on a 
the maintenance 
amino acid mixture 
occurred over a 90 min time period and could be inhibited by 
puromycin (Which acts by inhibiting assembly of new proteins by 
ribosomes), and cycloheximide (which acts by inhibiting DNA and 
RNA synthesis) (Vasquez, 1974). Hypothalamic tissue incubated 
under these conditions thus shows considerable metabolic activity. 
The thickness of the hypothalamic block kept + 1mm was to so 
that the maximum diffusion distance of oxygen to reach all cells 
was 0.5mm which is considered adequate for metabolic requirements 
(Bradbury, Burden, Hillhouse et. al. I 1974 ; Mcilwain, 1975). 
A pre incubation time of 60 min was chosen because by this time 
release of CCK 8 had decreased to a low value. This time period 
was well within that es tab I ished for viability. A time-course of 
release showed both basal and K+ induced release of CCK 8 occurred 
throughout a 30 mm period of incubation, release being diminished 
between 30 - 45 mm. Thus 30 min was chosen as the maximum 
acceptable incubation time, degradation or reuptake of released 
130 
CCK 8 probably occurring after that time period. The good 
recovery of added CCK8 after 30 min of incubation suggests 
that degradative enzymes were not active in the medium during 
the first 30 min, either because of the period of pre incubation 
in a large volume of medium, or because of the use of a 
tissue block rather than a broken cell suspension. 
Using this system we have shown that CCK
8 can be released 
by the depolarising stimuli, 60 mM KCI and 75 pM veratrine (the 
mechanisms of action have been discussed in Chapter Four). The 
calcium -dependence of this release 
of 60 mM KCI stimulated release in 
the Ca++ chelating 
IS 
a 
demonstrated 
low Ca++ 
by the inhibition 
medium or ,n 
the presence of agent EGTA. A classical 
role for Ca++ in the neurosecretory process is also suggested by 
the stimulation of release elicited by the Ca-++ ionophore A23187. 
However, since this ionophore is also known to increase fluxes of 
other cations through membranes it is also possible that the effect 
is due to a depolarisation. 
The material released, from the hypothalami, coeluted with 
Sephadex G-50 (sf) chromatography and diluted in parallel 
CCK8 on 
to CCK 8 
standards in the radio immunoassay. No gastrin-1 ike material was 
found even though low concentrations have been found in the hypo-
thalamus (Rehfeld, 
CCK 33 and CCK 4 
rendering the assay 
1978c). In addition, other CCK moieties 
crossreoct poorly with the antiserum used, 
relatively specific for CCK 8 • 
such 
thus 
as 
The function of CCK 8 in the hypothalamus is as yet unknown. 
CCK 8 hos been reported to cause satiety when injected into various 
animals and this may occur via the hypothalamic satiety centre. 
Vijayan, Samson and McConn (1979) demonstrated that CCK
8 when injected into the third ventricle of rots caused release of GH and 
suppression of LH and TSH but could not demonstrate a direct 
effect of CCK 8 on the isolated pituitary. 
Berelowitz et. al. , (personal communication). 
Th is was confirmed by 
In contrast Morley, 
Mel med, Briggs et. al. (1979) have demonstrated GH release from 
incubated rat pituitaries in response to CCK 8 . Our data shows 
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that CCK 8 is released rn response to dopamine. We were unable 
to demonstrate any negative feedback on dopamine - stimulated release 
by either GH or SRIF. Dopamine causes SRIF release rn these 
preparations and inhibits GH secretion in the rat rn vitro. It 
was of interest, however, that the dopamine-sti mulcted CCK
8 release 
appeared to be dependent upon noradrenergic modulation as demon-
strated by our findings that phentolamine at physiological concentra-
tions inhibited dopamine -stimulated release. This noradrenergic 
modulation could be via a number of pathways. 
l. 
2. 
3. 
That the effect is not dopamine mediated but is trans-
formed within the tissue by the enzyme dopamine-p-hydroxy-
lase to noradrenaline and thus is a noradrenaline effect. 
Without specific experiments using dopamine agonists and/or 
a dopamine-p-hydroxylase blocker this possiblility cannot be 
excluded (Fig 6.8 a). 
That the dopamine effect is mediated through an inter-
vening noradrenergic neurone. The blocking of this neurone 
by phentolamine blocks both the dopamine and noradrenaline 
stimuli (Fig 6. 8 b). 
That the dopamine has a direct effect on CCK 8 release 
but is dependent on 
i) a pre-synaptic positive modulatory effect of a nora-
drenergic neurone or 
ii) on a post-synaptic modulation of the effect of dopamine 
on the CCK neurone (Fig 6.8 c). 
Thisa. data is not sufficient to preclude the possibility of CCK 8 from 
having an effect on GH secretion either at a hypothalamic or 
pituitary level. Further investigations need to be done to investigate 
the interrelationship of the dopamine and noradrenaline pathways in 
the control of GH secretion. 
Thus in conclusion the rat hypothalamus appears viable m vitro under 
the conditions of incubation, as assessed by linear oxygen consumption 
and linear incorporation of labelled amino acids over time. Depolar-
132 
rising stimuli of 60 mM KCI and 75 pM veratrine caused release of 
CCK 8 which was 
calcium- dependent. Dopamine at physiological 
concentrations, stimulated CCK8 release via a
 noradrenergic pathway 
as demonstrated by the inhibition of release with phentolamine. 
Fig 6.8 
.a. .b. 
DA 
~ 
): 
i > 
i,' 
Noradrenergic modulation of dopamine-stimulated CCK 8 release could 
be via 
a} transformation of dopamine (DA) to noradrenaline 
(NA) within the neurone. 
b) an intervening noradrenergic neurone. 
c) a pre- (?) or post-synaptic (?) positive modulatory 
noradrenergic neurone. 
P represents inhibition of release of CCK 8 by phentolamine (10-
6M 
and 10-8M). 
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SUMMARY 0 F CONCLUSIONS 
The aim of the study was to show that CCK 8 was both a 
neuromodulator and a hypothalamic hormone in the central nervous 
system. 
In order to define a possible neuromodulatory or neurotransmitter 
role for CCK 8, the presence and release of the peptide through-
out the central nervous system was examined. The uneven and 
widespread distribution of in rot brain was confirmed along 
with its localisation in the synaptosome fraction of rot brain 
homogenates prepared from hypothalamus, striotum, cortex and thala-
mus. A calcium-dependent release of CCK 8 from these areas has 
been demonstrated. 
CCK 8 
was re leased m a calcium-dependent manner from per if used 
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cortical synaptosomes. Dopamine and acetyl choline caused a signifi-
cant release of CCK
8
, thus showing neurotransmitter control of CCK 8 
release. No release occurred in response to the higher concentra-
tions implying that high 
ore able to reverse the 
dopamine and acetyl choline concentrations 
effect of the lower concentrations. It 
been shown that CCK-1 ike peptides and dopamine coexist in the 
same neurone and thus it has been suggested that the peptide is 
has 
released together with dopamine and may be part of an inhibitory 
system modulating dopamine release via an action on autoreceptors. 
Evidence for CCK8 being a hypothalamic hormone relates to experi-
ments involving the in vitro incubated hypothalamus. CCK 8 was 
shown to be released from the in vitro incubated hypothalamus by 
depolarising stimuli in a calcium-dependent manner. The demon-
strotion rn this laboratory that CCK 8 causes GH release from isolated 
rot pituitaries suggests that CCK is a possible regulator of GH. 
The dopamine-stimulated release of CCK
8 
which appeared to be 
dependent upon a norodrenergic pathway could not be inhibited by 
rGH or SRIF. Thus, if CCK 8 is a GH releasing factor, the 
regulation of GH does not appear to operate via inhibition of CCK 
release by rGH or SRIF. This data does not however preclude 
the possibility of CCK 8 from having an effect on GH secretion 
either at a hypothalamic or pituitary level. 
Identity of the released immunoreactive material was demonstrated 
by coelution on Sephadex G-50 (sf) chromatography with synthetic 
CCK 8 and parallelism with dilutions of synthetic CCK 8 . The 
low crossreactivity of other CCK Moieties with the antisera used 
in this study does not enable conclusions to be drawn regarding 
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the importance of other molecular weight forms of CCK which may 
be present. 
In conclusion the results of the in vitro experiments presented in 
this study suggest a probable important role for CCK 8 in the rat 
CNS. The demonstration that neurotransmitters affect CCK 8 release 
provides further evidence for CCK 8 being a modulator of neuronal 
function. 
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